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Abbreviations 
1,25(OH)??D   1,25-dihydroxyvitamin D 
1-OHase  25-hydroxyvitamin D-1?-hydroxylase, CYP27B1 
24-OHase  25-hydroxyvitamin D-24-hydroxylase, CYP24A1 
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FGF-23  fibroblast growth factor 23 
FINRISK population survey on risk factors of chronic, noncommunicable 
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FOXP3   forkhead box P3 
FPG fasting plasma glucose 
FPI fasting plasma insulin 
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HIV human immunodeficiency virus 
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IA2 insulin autoantigen 2 
IAA insulin autoantibody 
ICA islet cytoplasmic autoantibody 
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LNCaP   prostate cancer cell line (lymph node carcinoma of the prostate) 
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MCF-7   breast cancer cell line (Michigan Cancer Foundation-7) 
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MyD88  Myeloid differentiation primary response gene 88 
NF-?B   nuclear factor-?B 
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RANTES  regulated upon activation, normal T-cell expressed and secreted 
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SPF   sun protecting factor 
SPSS Statistical Package for the Social Sciences 
STRIP  intervention project for coronary heart disease risk factors 
(sepelvaltimotaudin riskitekijöiden interventioprojekti) 
T1D    type 1 diabetes 
T2D type 2 diabetes 
Th    T helper 
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TNF-? tumor necrosis factor-? 
TR    thyroid receptor 
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1 Introduction 
1.1 Vitamin D 
1.1.1 General definition  
Vitamin D is a pro-hormone which is either synthesized in the skin due to sunlight or 
artificial ultraviolet light (UVB=290-315 nanometers) exposure, or obtained from the 
diet (reviewed in Holick, 2003). Its major roles are in calcium homeostasis where it 
increases the absorption of calcium from the intestine. When the calcium concentration 
is too low, vitamin D signals through osteoblasts for osteoclast precursors to dissolve 
calcium (reviewed in Holick, 2003). The most important role of vitamin D is to regulate 
the metabolism of calcium and phosphate (reviewed in Barnes et al., 2006). It enhances 
the absorption of calcium and phosphorus from the small intestine into the enterocytes 
(see Deluca and Cantorna, 2001). When parathyroid hormone is present vitamin D 
mobilizes  calcium from the  bone  and  improves  the  renal  reabsorption  of  calcium (see  
Deluca and Cantorna, 2001). Other tissues are also affected by vitamin D. It has been 
shown that  vitamin  D also  regulates  cell  growth,  proliferation  and  differentiation  (see  
Holick, 2005). Cells regulated by vitamin D are among others enterocytes, osteoblasts, 
keratinocytes, parathyroid cells, monocytes and lymphocytes (see Deluca and Cantorna, 
2001). Other cells which are thought to be regulated by vitamin D are islet cells of the 
pancreas, endocrine cells, ovarian cells, developing myoblasts, skin fibroblasts and 
aortic endothelial cells (see Deluca and Cantorna, 2001).  
Vitamin D is a 9,10-secosteroid and it has two main forms; vitamin D? (D?) and 
vitamin D? (D?). D? is derived from a plant sterol ergosterol and D? is formed from 7-
dehydrocholesterol (Figure 1 and Figure 2). D? differs  from D? in the way that it has 
one more double bond and one more methyl group than D?.  
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A)      B) 
Figure 1. Cholesterol (A) and Cholecalciferol (Vitamin D?) (B). 
 
    
A)      B) 
Figure 2. Ergosterol (A) and Ergocalciferol (Vitamin D?) (B). 
 
Vitamin D has two major metabolites; 25-hydroxyvitamin D (25(OH)D) and 1?,25-
dihydroxyvitamin D (1,25(OH)?D) (Figure 3) (Blunt et al., 1968, Haussler et al., 1968). 
25(OH)D is an interesting metabolite to measure because it represents the overall 
vitamin D status (see Bouillion et al., 1998). 1,25(OH)?D is the active form of vitamin 
D and its activity mainly goes via the nuclear vitamin D receptor (VDR), which is 
present in many tissues (reviewed in Deluca and Cantorna, 2001). 
 
    
A)      B) 
 
Figure 3. 1?,25-dihydroxyvitamin D? (1,25(OH)?D?) (A) and 25-hydroxyvitamin D? (25(OH)D?) 
(B). 
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Naturally vitamin D is found in a few foods like fish and fish liver oils. The form of 
vitamin D In fish is D?. In mushrooms on the other hand the main form found is D? 
(Table 1). The estimated vitamin D content of different foods varies from author to 
author  and  there  are  no  exact  values  for  that.  Holick  (2007)  estimated  the  content  of  
vitamin D in 100 grams (g) of sardine to be 7.5 micrograms (µg) whereas Bouillion et 
al. (1998) estimated the value to be as high as 40.0 µg. Egg yolk has believed to contain 
much vitamin D but now it has been estimated to content only 2.2 µg per 100 g (Table 
1). Eel, lamprey and sander seem to contain more vitamin D that other fish. Chanterelle 
seems to be the best plant source for vitamin D. Fish roe, which is a very popular food 
in Finland also contains a good amount of vitamin D (9.5 µg/100 g). The best meat 
source for vitamin D is chicken with a low content of 0.7 µg/100 g. 
 
Table 1. Vitamin D content in different foods in Finland. Source: www.fineli.fi. 
Food Concentration µg / 100 g  
 
Fish liver oil (Möller, 100 ml) (D?) 200.0 
Eel (D?) 25.6 
Lamprey (D?) 25.6 
Sander (D?) 24.6 
Lavaret (D?) 22.1 
Baltic Herring (D?) 18.7 
Bream (D?) 14.0 
European Cisco (D?) 13.0 
Chanterelle (D?) 12.8 
Fish average, Baltic Herring/European Cisco/Perch/Pike (D?) 10.3 
Roach (D?) 10.0 
Baby`s milk formula, mean, powder (D?) 9.6 
Fish roe, mean (D?) 9.5 
Rainbow trout file, low fat, oven baked (D?) 9.1 
Salmon file, fried (D?) 8.7 
Anchovy (D?) 5.7 
Rufous milk-cap (D?) 5.5 
False morel (D?) 4.4 
Mushroom, boletus, russula (D?) 4.4 
Pike (D?) 3.0 
Penny bun bolet (D?) 2.9 
Egg-butter (D?, D?) 2.8 
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Fried egg (D?, D?) 2.5 
Boiled egg (D?, D?) 2.2 
Trout (D?) 2.1 
Flounder (D?) 0.7 
Chicken (D?) 0.7 
French salad dressing, oil, egg yolk, sugar, salt (D?, D?) 0.5 
 
Many foods have been fortified with vitamin D (Table 2.) due to the seasonal variation 
in vitamin D synthesis in the skin and the growing prevalence of vitamin D deficiency 
and insufficiency in the population all over the world. Chen et al. (2007) studied the 
vitamin D content of fortified milk samples from the United States and British 
Columbia, Canada and found out that 49% of them contained less than 80% of the 
labeled content and 14% did not contain any vitamin D. This elicits the question if 
consumers who rely on fortified products really get adequate vitamin D requirement. In 
Finland milk products and spreads are fortified with vitamin D except for organic 
products which are not fortified (www.fineli.fi). The products in Finland are fortified 
with  vitamin  D?. Spreads and margarines usually contain vitamin D in concentrations 
between 5.3 µg/100 g and 10 µg/100 g. Milk products on the other hand contain vitamin 
D concentrations of 0.5 µg/100 g. Milk products and spreads are important vitamin D 
sources for the Finnish population.   
 
Table 2. Vitamin D content in different fortified foods in Finland. Source: www.fineli.fi.   
Fortified foods Concentration 
µg/100 g  
Spread 23% becel pro-activ extra light 10.0 
Spread 30% keiju 10.0 
Spread 35% becel pro-activ 10.0 
Spread70 % mean 10.0 
Spread 70% keiju lactose free 10.0 
Margarine 40% keiju light lactose free 10.0 
Margarine 60 % kultarypsi  10.0 
Margarine 60% keiju normal salty 10.0 
Margarine, flora light 40 10.0 
Spread mixture 30 % oivariini balansia  10.0 
Baking margarine 80% liquid, mean 9.2 
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Margarine 40 % rainbow/eldorado 9.2 
Margarine 40 % mean  9.2 
Margarine 60 % mean 8.8 
Spread mixture 30% kevyt levi  5.3 
Baby`s milk formula, mean, ready to use 1.2 
Acidophilus sour milk, 2,5% fat, a-sour milk/ab-sour milk 0.5 
Gefilus-sour milk 1% fat 0.5 
Yogurt, unseasoned,  non-fat, low lactose 0.5 
Yogurt, unseasoned, a+, fat 2,5 %, low lactose 0.5 
Semi-skimmed milk 1,5% fat 0.5 
Semi-skimmed milk 1,5% fat, low lactose 0.5 
Buttermilk 0,3% fat 0.5 
Milk, calcium, skimmed  0.5 
Milk drink, lactose free, fat 1,5 g 0.5 
Milk drink, lactose free, skimmed  0.5 
Berry-/fruit-yogurt, fat 2 %, low lactose 0.5 
Skimmed milk 0.5 
Skimmed milk, low lactose 0.5 
Skimmed sour milk 0.5 
Skimmed milk, low lactose 0.5 
Whole milk 3,5% fat 0.5 
One-milk 1% fat 0.5 
 
Vitamin D supplements are usually recommended during the winter in Finland and 
different concentrations are available. Capsules containing 2.5 µg to 25 µg are available 
without recipe and capsules containing 200 µg are available when prescripted (Table 
3.). 
 
Table 3. Vitamin D content in supplements in Finland. Source: www.yliopistonapteeki.fi.  
Supplements Concentration (µg) 
Vitamin D? capsules 2.5, 5.0, 7.5, 10.0, 20.0, 25.0, 200 
Vitamin D? liquid 
supplement (ml) 
61.0 
Multivitamin capsules 5.0, 7.5, 10.0 
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Table 4. Vitamin D content from sun exposure. Modified from Holick, 2007. 
Other Concentration (µg) 
Exposure to sunlight, UVB radiation 0.5 minimal erythemal dose* (D3) 75.00 
*5-10 min exposure of the arms and legs to direct sunlight, depends on time of day, season, latitude, skin 
sensitivity 
 
The amount of vitamin D obtained from supplements and UVB exposure is illustrated in 
Table 3 and Table 4. Interestingly Chen et al. (2007) also found out, when studying the 
vitamin D composition in farmed and wild fish, that farmed salmon also contained 
vitamin D?. This can be due to feed which is used, but it can also elicit the question if 
the vitamin D content of fish and other foods has to be reevaluated.  
1.1.2 Metabolic Pathway of Vitamin D 
The two forms of vitamin D are metabolized almost similarly in the human body. The 
metabolic pathway of D? starts (when synthesized in the skin) with the conversion of 7-
dehydrocholesterol (7-DHC) to previtamin D? in the lipid bilayer of epidermal 
keratinocytes and dermal fibroblasts through UVB radiation (Holick et al., 1977, 
Holick, 2002). Due to additional UVB radiation previtamin D? is converted to inactive 
vitamin  D  metabolites  as  lumisterol  and  tachysterol  (see  Wolpowitz  and  Gilchrest,  
2006). This is the bodys precaution for preventing intoxication. Previtamin D? is heat-
induced converted to vitamin D? which no longer is sterically acceptable for the plasma 
membrane and gets ejected to the extracellular space (see Holick, 2002).  
Vitamin D? and D? are metabolized nearly similar in the human body, but more 
is known about vitamin D?. Differences have been found in vitamin D binding protein 
affinity (see Houghton and Vieth, 2006). One difference in metabolic activity is seen in 
the metabolites 1,24,25(OH)?D? and 1,24,25(OH)?D?. The D? metabolite has the ability 
to bind to the vitamin D receptor but the D? metabolite is an inactive metabolite unable 
to bind (see Houghton and Vieth, 2006). Vitamin D obtained from the diet is transported 
from the intestine via lymph veins to the liver in chylomicrons (see Holick and Chen, 
2008, see Bouillon et al., 1998). In the blood circulation vitamin D and its metabolites 
are bound mainly to vitamin binding protein (DBP) (25(OH)D and 1,25(OH)?D 80-
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90%) or albumin (25(OH)D and 1,25(OH)?D 10-20%) and lipoproteins (see Zerwekh, 
2008). Vitamin D can be stored in adipose tissue and bound to DBP it can be absorbed 
by cells via endocytosis where DBP is degraded (see Holick, 2007, see Zerwekh, 2008). 
According to Bouillon et al. (1998) the cell surface lipoprotein-like receptor involved in 
the process is megalin and is at least present in kidney cells. This process was proved by 
Nykjaer et al. (1999). The half life of vitamin D is only ~24 h and similar to that the half 
life of 1,25(OH)?D is ~4 h (see Zerwekh, 2008). The amount of 1,25(OH)?D is also 
tightly regulated by several factors discussed further. In contrast the half life of 
25(OH)D is ~3 weeks and it is not significantly regulated, which makes it clear why to 
measure this metabolite from the blood. Vitamin D metabolites are rapidly absorbed by 
cells when they are not bound to DBP. 
Once vitamin D is in the circulation it is transported to the liver, where it is 
converted to 25(OH)D by vitamin D-25-hydroxylase (CYP27, CYP2D25) (see Holick, 
2007, van Etten and Mathieu, 2005). CYP27 is a sterol-27-hydroxylase (cytochrome P-
450) with many functions and it is encoded by a gene located on human chromosome 2 
(see Bouillon et al., 1998). It may have up to four different isoforms which act in 
vitamin D metabolism (CYP27A1, CYP2R1, CYP3A4 and CYP2J3) (Prosser and 
Jones, 2004). Besides 25- or 24-hydroxylation of vitamin D it can additionally, as a 
main function, do side-chain hydroxylations, especially 27-hydroxylation of bile acid 
biosynthesis metabolites and cholesterol. It is mainly found on the mitochondrial 
membrane of hepatocytes (reviewed by Jones et al., 1998). This enzyme is also found in 
other tissue cells like the duodenum, the adrenal gland, the lung and macrophages (see 
Bouillon et al., 1998). The synthesis of the enzyme in the liver is apparently only 
loosely regulated (see Jones et al., 1998). 25(OH)D is not the main active metabolite 
and must be converted into 1,25(OH)?D.  25(OH)D  can  also  be  converted  to  
24R,25(OH)?D by 25-hydroxyvitamin D-24-hydroxylase (encoded by CYP24A1 gene) 
(see Wolpowitz and Gilchrest, 2006, Lou et al., 2009). 
The hydroxylation of 25(OH)D into 1,25(OH)?D is catalyzed by the enzyme 25-
hydroxyvitamin D-1?-hydroxylase (1-OHase encoded by the CYP27B1 gene) in the 
kidney mainly. CYP27B1 is located on chromosome 12q13.1-q13.3 (reviewed by Bailey 
et al., 2007). Other tissues which produce 1,25(OH)?D are keratinocytes, 
immunological cells like monocytes, glial cells, bone and pneumocytes (Bouillion et al., 
1998). The synthesis of 1,25(OH)?D is tightly regulated. Some regulative factors are 
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serum phosphorus, calcium (and therefore PTH) and fibroblast growth factor (FGF-23) 
(see Holick, 2007). The metabolite also decreases its own synthesis and increases its 
degradation by increasing the production of 25-hydroxyvitamin D-24-hydroxylase (24-
OHase or CYP24) (see Holick, 2003). The metabolic pathway is illustrated in Figure 4. 
The water-soluble calcitroic acid is excreted in the bile (see Holick, 2007). 
Figure 4. The metabolic pathway of vitamin D.  
 
1.1.3 The biological functions of vitamin D 
Vitamin D and its metabolites are mostly bound to their vitamin D binding protein 
(DBP) in the bloodstream. When vitamin D, or its active metabolite 1,25(OH)?D, is 
absorbed into the cells DBP is degraded and 1,25(OH)?D can act on transcription 
through its nuclear receptor the vitamin D receptor (VDR). The VDR has one ligand 
binding and one DNA binding domain. The main role of vitamin D is in calcium 
homeostasis through parathyroid hormone (PTH) but vitamin D has been shown to 
affect many other tissues and cells too for example the immune system. 
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The vitamin D binding protein (DBP) and vitamin D transport in the bloodstream 
The vitamin D binding protein was discovered by Thomas et al. (1959) when they 
studied the serum half-life of vitamin D and related metabolites. They suggested that the 
fact that vitamin D was stable in serum but not in aqueous solutions must be due to a 
macro-molecule to which it is bound in serum. Daiger et al. (1975) suggested that a 
protein identified in the late 1950`s called group-specific protein was the same protein 
that bound and carried vitamin D (DBP) in serum. They considered that both were 
synthesized in the liver and had similar electrophoretic mobility. The complete amino 
acid structure was determined in 1986 by Schoentgen et al. (1986). They conducted that 
DBP  was  a  458  amino  acid  58  kilodalton  (kDa)  globulin  protein.  The  gene  encoding  
DBP  (Gc) is located on chromosome 4q11-q13. Uniprot defines DBP as a globular, 
multifunctional protein found in plasma, ascitic fluid, cerebrospinal fluid, and urine and 
on the surface of many cell types. According to Uniprot DBP, besides carrying vitamin 
D metabolites in the bloodstream, also prevents polymerization of actin by binding its 
monomers. DBP can bind to membrane-bound immunoglobulin (Ig) on the surface of 
B-lymphocytes and associate with IgG constant fragment (Fc) receptor on the 
membranes of T-lymphocytes (www.uniprot.org). Verboven et al. (2002) determined 
the structure of DBP and its vitamin D binding site by bioinformatic means (Figure 5). 
They solved the structure to 2.3 Å resolution and defined that the DBP has a ?-helical 
structure and three similar domains. The vitamin D binding site is located in domain one 
and  consists  of  helices  1  to  6.  The  reason  why  DBP  is  able  to  bind  vitamin  D  is  by  
Verboven et al. (2002) due to its first domains helical structure differences compared 
with human serum albumin (HSA). The fourth helix of HSA is closer to helices two and 
three and therefore leaves no space for vitamin D to bind. They considered that the 
possibility to bind actin is also due to DBPs different structural orientation. They 
characterized the vitamin D binding site as a hydrophobic region where the 25-OH 
group forms a hydrogen bond with the Tyr 32 and the 3-OH group forms hydrogen 
bonds with the Ser 76 and Met 107. The amount in that the site was occupied by 
25(OH)D was estimated by them to be 55%.  
  
18
 
Figure 5. Vitamin D binding protein bound to 25(OH)D? (Verboven et al., 2002). 
 
Interestingly the binding site in DBP is not similar to the binding site in the vitamin D 
receptor  (VDR)  which  may  be  the  reason  for  their  different  affinity  to  vitamin  D  
metabolites. Haddad et al. (1993) showed that DBP was a specific carrier for newly skin 
synthesized vitamin D rather than vitamin D obtained from the diet. They suggested that 
endogenously synthesized vitamin D was longer available in the bloodstream than 
vitamin D obtained from the diet which to their opinion was rapidly transported to the 
liver for swift metabolism. This resulted according to them to a faster clearance of 
vitamin D from the body due to appearance of water-soluble conjugates. They also 
showed  that  DBP  was  the  main  carrier  of  vitamin  D  and  its  metabolites  in  the  blood  
circulation. When vitamin D metabolites are free of DBP they enter the cells 
immediately through diffusion due to their lipophilic character. 
 
The endocytotic uptake of vitamin D into cells 
The mechanism which enables the metabolic pathway of vitamin D to continue in the 
kidney was characterized by Nykjaer et al. (1999). They used megalin knock-out mice 
to identify that megalin was the receptor for DBP-vitamin D complex in kidney cells. 
Megalin is a multifunctional receptor similar to the low-density-lipoprotein (LDL) 
receptor. Reviewed by Nykjaer et al. (1999) megalin is expressed in the 
neuroepithelium and in proximal tubular cells of the kidney and its ligands are 
lipoproteins, proteases and protease inhibitors. They found that 25(OH)D-DBP 
complexes were filtered through the glomerulus and absorbed into the epithelial cell by 
endocytosis. In the cell the complex is delivered to lysosomal compartments and DBP is 
degraded. The free 25(OH)D is then either further metabolised or released to the 
interstitial fluid where it can again bind DBP. Nykjaer et al (1999) proved that megalin 
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is essential for the uptake of 25(OH)D-DBP in megalin deficient mice. These developed 
vitamin D deficiency and bone disease due to the absence of megalin. 
 Later it has been proven that megalin is not the only receptor for DBP. Verroust 
et al. (2002) reviewed that another important endocytic receptor is cubilin. Cubilin and 
megalin function together in the endocytic absorption of vitamin D and minimize the 
urinal loss of vitamin D (see Verroust et al., 2002). Cubilin is a 460 kDa glycoprotein 
receptor with no transmembrane part (see Verroust et al., 2002). It is believed that 
cubilin facilitates the megalin-mediated absorption of vitamin D metabolite-DBP 
complexes. Driel et al. (2006) showed that megalin and cubilin are not only expressed in 
the endocytic apparatus of epithelial cells of the renal proximal tubule but also in other 
cells like bone cells. 
 Free vitamin D metabolites are also thought to enter cells directly by diffusion 
(see Verroust et al., 2002). When further metabolized vitamin D metabolites are 
secreted at the basolateral membrane they are either secreted bound to newly 
synthesized carrier proteins or as free metabolites which first in plasma bind carrier 
molecules (see Verroust et al., 2002). 
 
The active metabolite 1,25(OH)?D 
The active metabolite of vitamin D was determined by Haussler et al. (1968) by silicic 
acid column chromatography of whole mucosa and mucosa chromatin from rachitic 
chicks which had been administrated with radioactively labelled vitamin D?. They 
identified at least three possible metabolites from which one was especially biologically 
active and located in the chromatin (1,25(OH)?D). Another metabolite with some 
biological activity was identified but it was not localized in the nucleus. They assumed 
it to be an intermediate between vitamin D and the active compound (possibly 
25(OH)D). A third peak was characterized by Haussler et al. (1968) as a heterogenous 
collection of other and former mentioned metabolites. Tsoukas et al. (1984) showed that 
1,25(OH)?D has a function as an immunosuppressing agent by suppressing interleukin-
2 (IL-2). They also showed that 1,25(OH)?D inhibited the growth of mitogen-activated 
lymphocytes. According to Deluca and Cantorna (2001) the main proven target cells for 
1,25(OH)?D? are the intestinal enterocytes, osteoblasts, distal renal cells, keratinocytes 
of the skin, promyelocytes and monocytes, lymphocytes, colon enterocytes, shell glands 
and chick chorioallantoic membrane. They suggested that putative target cells are islet 
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cells in the pancreas, endocrine cells in the stomach, pituitary cells, ovarian cells, 
placenta cells, epididymis cells, cells in the hypothalamus, developing myoblasts, aortic 
endothelial cells and fibroblasts. According to Holick (2005) the main actions of 
1,25(OH)?D in calcium homeostasis are to increase the intestinal calcium absorption 
and to mobilize calcium stores from the skeleton. Holick (2005) pointed out that studies 
have shown that 1,25(OH)?D helps to regulate cell growth and maturation, stimulates 
insulin secretion, inhibits renin production and affects T- and B-lymphocytes as well as 
macrophages. 
  
The Vitamin D receptor 
The vitamin D receptor was first found and isolated from the chromatin fraction of 
rachitic chick intestinal mucosa cells by Haussler and Norman (1969). They 
characterized it as a receptor with significant amounts of RNA and many possible forms 
with the molecular weight varying from 50 kDa to over 200 kDa. They confirmed it to 
bind the active form and other forms of vitamin D.  
The active form of vitamin D, 1,25(OH)?D, interacts with cells mainly through 
its nuclear receptor the vitamin D receptor (VDR). The VDR was cloned by Baker et al. 
(1988)  and  they  concluded  that  the  receptor  is  part  of  the  superfamily  of  trans-acting  
transcriptional regulatory factors. Other receptors which belong to this family are 
steroid and thyroid hormone receptors. The human VDR gene is located on 
chromosome 12q12-q14 and the human VDR has 427 amino acids and a molecular 
mass  of  ~50  kDa.  VDR  is  a  homodimer  when  vitamin  D  is  not  bound  to  it  and  a  
heterodimer (together with Retinoic X receptor) when vitamin D binds 
(www.uniprot.org). These receptors have a highly conserved DNA-binding domain with 
two zinc fingers at their amino terminal which is rich in cysteine, lysine and arginine 
residues (see Jones et al., 1998, Baker et al., 1988, Brown et al., 1999). The ligand-
binding domain is located at the carboxyl terminal. The DNA-binding domain between 
VDR and steroid and thyroid hormone receptors is 40% conserved according to Baker 
et al. (1988). They also suggested that this domain is harboring both DNA binding and 
transcriptional activities. In their study they confirmed that the VDR affinity lowers in 
following order; 1,25(OH)?D, 25(OH)D, 24R,25(OH)?D, 1?,24(R),25(OH)?D, 
??(OH)?D and vitamin D. The different domains are illustrated in Figure 6 and Figure 
7. 
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    DNA binding domain   Ligand binding domain 
 
 
 
Figure 6. Vitamin D receptor. 
 
Norman et al. (1999) designed a three-dimensional structure of the VDR ligand binding 
domain (LBD) with sequence alignment to the LBD of the rat ?-helical thyroid receptor 
(TR) using X-ray crystallography. The human VDR LBD residues 142-427 were 
aligned with the rat TR LBD residues 157-410 manually. The model of the human VDR 
LBD created was an elongated globular protein with 12 ?-helical elements linked by 
short loops forming an anti-parallel helical triple sandwich.  
 
Figure 7. VDR DNA binding domain (A) bound to DNA and vitamin D binding domain (B). 
 
Norman  et  al.  (1999)  showed  that  the  interior  surface  of  the  LBD  was  comprised  by  
hydrophobic residues (H305, S306, Y401, S405 and T415) which interact with 
427 
192 21 96 
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1,25(OH)?D groups 1?-OH, 3?-OH and 25-OH to form hydrogen bonds. According to 
them the natural mutation in H305Q of VDR, results in 80% decreased ligand affinity. 
The reason for this might be that this residue is particularly important to a specific 
portal opening. They concluded that the conformation of helix 12 in the receptors 
docking site is changed conformationally when the ligand binds to the receptor. The 
helix 12 creates a portal where it is rotated out and down in an unoccupied receptor and 
up to interact with helixes 3 and 5 in an occupied receptor to close the portal. They 
showed that it facilitates the entrance through the portal if the ligand is in optimal 
conformation. They considered that the conformation favoured for entrance could be a 
“slim” 1?,25(OH)2-6-s-trans-D? form while the optimal form for binding could be 
closer to the classic “pudgy” form 1?,25(OH)2-6-s-cis-D?. It is known that the 
conformational flexibility of 1,25(OH)?D is due to its A-ring and the rotation around the 
6,7 carbon single bond. The conformational changes are possible due to the fact that 
vitamin D and its metabolites do not have a 9,8 carbon bond between the A- and the B-
ring.  Norman et  al.  (1999)  considered  that  it  was  not  clear  if  the  volume of  the  VDR 
LBD interior (~620 Å³) was enough for the ligand (375 Å³) to change conformation 
from trans-form to cis-form. The LBD is also responsible for dimerization with the 
retinoic X receptor (RXR) after binding 1,25(OH)?D. This heterodimeric receptor then 
binds to vitamin D responsive elements (VDRE) and induces transcription of target 
genes with the help of histone release and transcription factors (reviewed by Jones et al., 
1998). The mechanism is illustrated in Figure 8. 
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Figure 8. The activating mechanism of vitamin D in the nucleus. 
 
As reviewed by Jones et al. (1998) the RXR is required as a cofactor to establish VDR-
RXR binding to VDREs. It has been shown that VDREs are usually composed of two 
repeats of the sequence AGGTCA separated by one to several non-specific bases. The 
most common VDREs from genes up-regulated by VDR have three separating bases 
between the half-sites (see Jones et al., 1998). The first VDRE isolated was from the rat 
osteocalcin gene (Demay et al., 1990). Jones et al. (1998) reminded that the RXR 
usually binds to the 5`-half-site of the VDRE and the VDR to the 3`-half-site. Binding 
of the VDR-RXR to the VDRE, results in bending of the VDRE (Kimmel-Jehan et al., 
1999). Jones et al. (1998) speculated that this bending and the release of histones may 
be the combination that makes the promoter of target genes more reachable for 
transcription factors. VDR has been shown to interact with other cofactors too but it is 
not clear according to Jones et al. (1998) if it binds them also. 
 Lou et al. (2009) showed that VDR also binds 25(OH)D. The intermediate 
metabolite showed direct anti-proliferate effects on human LNCaP prostate cancer cells 
and gene regulatory properties in primary mouse kidney, skin, prostate and human 
MCF-7 breast cancer cells therefore indicating that not only 1,25(OH)?D has gene 
regulatory and anti-proliferative properties. This could be a promising result considering 
therapeutic applications. The administration of 1,25(OH)?D has showed some severe 
side effects in patients like hypercalcemia and hypercalciuria and therefore the use of 
25(OH)D instead would be a possible approach (Lou et al., 2009). 
 One study also showed that there are intracellular proteins that enhance vitamin 
D mediated transcriptional activation (Adams et al., 2004). Two types of proteins were 
identified were the first family was considered to be called heterogeneous nuclear 
ribonucleoproteins (hnRNPs) and the second to be named intracellular vitamin D 
binding proteins (IDBPs). The hnRNPs were identified as pre-mRNA interacting 
proteins which show cis-acting, trans-dominant regulation of vitamin D dependent gene 
regulation.  
   
Vitamin D and Calcium homeostasis 
The major role of vitamin D in calcium homeostasis is mediated through the active 
metabolite and hormone 1,25(OH)?D. Low levels of plasma calcium stimulate the 
production of PTH from the parathyroid glands which then bind to osteoblasts and 
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kidney cells to enhance the production of 1,25(OH)?D through 1?-hydroxylase 
(reviewed in Deluca and Cantorna, 2001). In the intestine 1,25(OH)?D induces the 
expression of calbindin D-9K, an epithelial calcium channel (see Holick, 2005). Added 
to that 1,25(OH)?D also regulates several other calcium related genes and their protein 
products. These include according to Bouillion et al. (1998) osteocalcin, osteopontin, 
collagen type 1, matrix gla protein, ???3 integrin and VDR in the bone, calbinding D-
9K and 24-hydroxylase in the kidney and PTH and calcitionin in the endocrine cells and 
parathyroid cells.  
Vitamin D deficiency caused secondary hyperparathyroidism results in wasting 
of skeleton leading to osteoporosis or osteomalacia (see Holick, 2005). The bone 
density is decreased which is called osteopenia and this is investigated by for example 
X-ray bone density measurement. The loss of mineralization is caused by loss of 
phosphorus into the urine which results in lower serum phosphorus levels. This leads to 
inadequate calcium-phosphorus products which causes poor or defective mineralization 
of the bone (see Holick, 2005). This can lead to rickets in children, where the poorly 
mineralized skeleton deforms under the body weight and classic bony rachitic 
deformities like bowed legs or knocked knees can form (see Holick, 2005). According 
to Holick (2005) the results in adults can lead to osteomalacia. This is a condition where 
the newly formed osteoid can not be properly mineralized and becomes hydrated. The 
calciumhydroxyapatite can not be formed in the matrix. This leads to a state where the 
osteoid is not able to provide support for sensory fibers in the periosteal covering and 
this causes either global or isolated throbbing, aching bone pain. 
The excess of vitamin D can lead to hypervitaminosis D and then to 
hypercalcemia where often symptoms like nausea, vomiting and polyuria are observed. 
The amount of calcium in the serum in hypercalcemia is thought to be over 2.6 mmol/l 
(reviewed in Holick, 2007). It has been estimated that S-25(OH)D concentrations over 
374 nmol/l can cause vitamin D intoxification (reviewed in Holick, 2007).  
 
Vitamin D and PTH 
Both 1,25(OH)?D and PTH play an important role in calcium homeostasis as discussed 
before. Secondary hyperparathyroidism is a condition where serum intact PTH (iPTH) 
concentration is elevated and the reason for this must not necessarily be hypercalcemia 
(Freaney et al., 1993). It can be caused by renal insufficiency in 1-?-hydroxylation, 
privational hypovitaminosis D or intestinal diseases with calcium malabsorption 
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(Freany et al., 1993, Kauppinen-Mäkelin et al., 2001). Freany et al. (1993) investigated 
the PTH concentrations in elderly subjects and concluded that secondary 
hyperparathyroidism linked to aging is caused by the decline in 1-?-hydroxylase activity 
and hypovitaminosis D, and can be moderated by vitamin D supplementation. 
Hypovitaminosis  D  can  be  defined  as  the  S-25(OH)D  concentration  where  S-iPTH  
begins to rise. This has varied in different studies (25 nmol/l (Freaney et al., 1993), 37.5 
nmol/l (Thomas et al., 1998) 50 nmol/l (Kauppinen-Mäkelin et al., 2001), 78 nmol/l 
(Välimäki et al., 2004)). 
 
Vitamin D and the immune system 
The role of 1,25(OH)?D in the immune system has been studied by Veldman et al. 
(2000). They found out that the VDR is specially expressed in T lymphocyte CD8 cells. 
Significant amounts were also expressed in CD4 cells. They suggested that the major 
target of 1,25(OH)?D in the immune system are CD8 cells. Jeffrey et al. (2009) studied 
the effect of 1,25(OH)2D on human CD4+CD25- T–cells. They found out that 
1,25(OH)?D inhibited production of interferon gamma (IFN-?), IL-17 and IL-21. T-cell 
division in contrast was not affected. Jeffrey et al. (2009) observed that 1,25(OH)?D had 
an enhancing effect on CTLA-4 and FOXP3 production. T-cells which were treated 
with 1,25(OH)?D suppressed the proliferation of normally responsive T-cells. Hewison 
et al. (2003) showed in their study that 1,25(OH)?D is capable in inhibiting the 
differentiation, maturation and activation of monocyte-derived dendritic cells. They also 
showed that 1,25(OH)?D is produced locally in dendritic cells and macrophages. 
Mathieu et al. (1994) showed that 1,25(OH)?D is able to decrease T lymphocyte helper 
cell (Th1 cell) infiltration in the pancreas. Equils et al. (2006) showed that 1,25(OH)?D 
may also be a potential adjuvant in the treatment of gram-negative bacterial infections. 
They showed that 1,25(OH)?D modulates the immune response of human microvessel 
endothelial cells and inhibits TLR4 agonist LPS-induced MyD88-dependent NF-?B 
activation. They also showed that 1,25(OH)?D inhibits proinflammatory cytokines, IL-6 
and IL-8, and CC-chemokine RANTES release. The VDR is presented constitutively on 
antigen-presenting cells (APCs) like macrophages and dendritic cells (DCs) and 
inducibly on lymphocytes following activation (van Etten and Mathieu, 2005). The 
  
26
25(OH)D?-1-?-hydroxylase is regulated differently in the kidney than in the 
macrophages according to van Etten and Mathieu (2005). They showed that in the 
kidney it is regulated by PTH and 1,25(OH)?D, and in contrast by immune signals like 
IFN-? in the macrophages. In DCs the enzyme is regulated by the maturation of these 
cells associated with p38 MAPK- and NF-?B. Th 1 cells secrete IFN-? and IL-2. IFN-? 
is important for APCs and T lymphocyte recruitment. IL-2 is a growth factor for T 
lymphocytes and promotes their activation and proliferation. When 1,25(OH)?D inhibits 
these, the profile of T helper cells shifts from Th1 to Th2, which secrete IL-4, IL-5, IL-
13, which have a more regulatory effect. 
The activation of an inflammatory response to infection is induced by 
granulocyte-macrophage colony-stimulating factor (GM-CSF), which activates mature 
granulocytes and macrophages. Van Etten and Mathieu (2005) summarized that 
1,25(OH)?D down-regulates this and also inhibits expression of the FasL ligand for Fas 
receptor, which together induce T cell apoptosis. 
1.1.4 Vitamin D Deficiency 
There are no global recommendations for sufficient serum vitamin D status. The 
concentration considered to indicate deficient status varies from under 20 nmol/l to 
under 50 nmol/l (table 5). The borders for insufficient status have been very different 
depending on source. Lamberg-Allardt and Viljakainen (2006) thought that sufficient 
status was between 50 and 79.9 nmol/l (table 5). Almost same values were suggested by 
Holick (2007) to indicate insufficiency. Wolpowitz and Gilchrest (2006) reviewed 
sources where insufficient status was either <37.5-50 or <80-100 nmol/l. Optimal status 
varies between over 50 nmol/l and over 100 nmol/l (table 5). The concentrations I will 
use in my work to characterize the results are the ones estimated by Lamberg-Allardt 
and Viljakainen (2006).  
 
Table 5. Different opinions on adequate and inadequate vitamin D status. 
Concentration Status Reference 
<50 nmol/l insufficient Lamberg-Allardt and Viljakainen, 2006 
50-79.9 nmol/l sufficient  
?80 nmol/l optimal  
?50 nmol/l (Lips) optimal Dawson-Hughes et al., 2005 
?70 nmol/l (Vieth) optimal  
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?75 nmol/l (Holick) optimal  
?75 nmol/l (Meurnier) optimal  
?80 nmol/l (Heany) optimal  
?80 nmol/l (Dawson-Hughes) optimal  
>374 nmol/l intoxication Holick, 2007 
<50 nmol/l deficient  
51-74 nmol/l insufficient  
<20-25 deficient Reviewed by Wolpowitz and Gilchrest, 2006 
<37.5-50 or <80-100 nmol/l insufficient  
above insufficient sufficient  
 
Factors that effect vitamin D status are age, clothing, skin pigmentation, sunscreen use, 
time of year and day, geographical location, and metabolic disorders. Obesity has also 
been associated with vitamin D deficiency. Hyppönen and Power (2006) investigated 
the relation between S-25(OH)D and body mass index (BMI). They concluded that high 
BMI was associated to low S-25(OH)D in a 45-year old population of 7198 subjects in 
Britain. They also suggested that the impact of S-25(OH)D on glucose metabolism may 
be dependent on body mass. The fact that vitamin D production in the skin is lower, or 
absent, in the winter in many regions, due to lower or absent UVB light, has been 
known for long. Kull et al. (2009) studied the seasonal variation of S-25(OH)D in 
Estonia in 367 randomly selected individuals (age ranged between 25 and 70 years). 
Their results showed that, mean S-25(OH)D concentration during summer was 59 
nmol/l and during winter 44 nmol/l. They compared their results to other studies where 
concentrations had been 67 nmol/l and 44 nmol/l (New Zealand, Rockell et al., 2006), 
79 nmol/l and 38 nmol/l (Japan, Ono et al., 2005), 84 nmol/l and 43 nmol/l (Italy, 
Carnevale et al., 2001) and 67-70 nmol/l and 40-45 nmol/l respectively (Germany, 
Scharla and Scheidt-Nave, 1996). These results show that there is a significant variation 
between winter and summer 25(OH)D status and these results can be dependably 
compared due to the fact that S-25(OH)D concentrations have been assessed with the 
same method (RIA, Diasorin). When the vitamin D production in the body due to UVB 
radiation is compared in older individuals it has been shown that a 70-year old person 
synthesizes only 25% of the amount a 20-year old person synthesizes vitamin D, 
exposed to the same amount of sunlight (see Holick, 2004).  This is due to the fact that 
the elderly have lower concentrations of 7-dehydrocholesterol in the skin. According to 
Holick (2004) a sunscreen of sun protecting factor (SPF) 15 reduces the skins capacity 
of producing vitamin D3 by over 98%. Chen et al. (2007) showed that the skin of a 
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person with type II converts about 5 to 10 times more 7-DHC to previtamin D? than the 
skin  of  a  person  with  type  V.  Vitamin  D  deficiency  in  children  causes  rickets  by  
inadequate calcium-phosphate products which cause mineralization defects (Holick 
2004). Symptoms of vitamin D deficiency can include bone and muscle pain and muscle 
weakness which often indicate the mineralization defect condition osteomalacia (see 
Holick, 2003). Secondary hyperparathyroidism is often associated with osteomalacia 
and it can increase the mobilization of the collagen matrix and mineral from the 
skeleton (see Holick, 2003). This can then lead to osteoporosis. Holick (2003) 
recommends one minimal erythemal dose (MED, 54 mJ/cm) two to three times a week 
by exposing face, arms and legs in order to receive adequate vitamin D requirement and 
storage in the body fat.  
According to van Groningen et al. (2010) the vitamin D? loading dose required 
to reach the serum 25(OH)D target level of Holick and Meurnier (75 nmol/l) can be 
calculated as follows: 
 
Dose (IU) = 40 x (75 - serum 25(OH)D?) x body weight. 
1.1.5 Vitamin D recommendations in Finland 
The vitamin D status is especially from October to May really low in Finnish people 
due to the absence of UVB light during this time (Hirvonen et al., 2004). Even in April 
and May the UVB light is very low in Finland (Lamberg-Allardt, 1984). In Finland 
vitamin D is specially recommended for infants and toddlers (0 to 3 years), pre-school- 
and school-aged children (3 to 15 years) and adults over 60 years (www.evira.fi). It is 
also recommended during pregnancy and lactation. The recommended time for 
additional vitamin D consumption from supplements is from the beginning of October 
to the end of March. For elderly people, in institutional care or homecare, who are not 
getting any outside exercise, vitamin D consumption is recommended all year-round 
(www.evira.fi).  
The main food sources for vitamin D for Finns are foods of fish (45%), dietary 
fats (21%) and liquid milk products. Dietary fats and liquid milk products are fortified 
with vitamin D (usually D?) (www.evira.fi, www.fineli.fi). The National Nutrition 
Council has recently suggested that the amount of vitamin D should be doubled in 
liquid milk products (from 0.5 µg/100 g to 1 µg/100 g) (www.evira.fi). 
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 Dietary fats have been fortified with vitamin D for the first time in Finland in 
1941. In the 1950`s the milk for Finnish school pupils was fortified with vitamin D but 
this was only a short term solution. Before 1964 the recommendation was 4000-5000 IU 
(100-125 ?g) per day. In 1964 the dose was lowered to 2000 IU (50 µg) and in 1975 to 
1000 IU (25 ?g) per day. The dose of 250 IU (5 µg) per day was suggested in 1992. 
Because many studies indicated that the vitamin D status of Finns was too low during 
the 1990`s, the National Nutrition Council (VRN; valtion ravitsemusneuvottelukunta) 
suggested in 2002 that the amount of fortified vitamin D into liquid milk products 
should be raised. In 2003 the new vitamin D fortification of liquid milk-products 
started. The recommendations for vitamin D intake have been changed in 2004 after that 
by the Ministry of Social Affairs and Health. It is estimated that new recommendations 
are soon to be made hence to the raising number in vitamin D deficiency all over the 
world. (www.evira.fi) 
 The current recommendation for vitamin D intake in Finland is 7,5 µg per day 
for 3 to 60 year-olds when it has earlier been 5 µg per day. The recommended dose for 
children under 3 years and pregnant or lactating women is 10 µg per day. The 
recommendation for the elderly over 60 years has just been raised (30.03.2010) to 20 µg 
per day. Interestingly labels of fortified products (milk) still seem to have old 
recommendations (5 µg). The highest recommended dose for individuals under 10 years 
is 25 µg per day, and for young adults and adults 50 µg per day (www.evira.fi). If one 
eats fish at least twice a week, drinks half a liter milk per day and uses vitamin D 
fortified dietary fats in cooking and on bread, there is no need to use vitamin D 
supplements to reach an adequate status of serum vitamin D (Lamberg-Allardt and 
Viljakainen, 2006). But if one of vitamin D sources mentioned is lacking, the use of 
supplements is needed. 
1.1.6 Vitamin D status in the healthy Finnish population  
Kauppi et al. (2009) studied the vitamin D status in Finnish healthy subjects and the 
association to ultrasound parameters considering bone health (broadband ultrasound 
attenuation (BUA) and speed of sound (SOS)). The number of subjects was 6035 (2736 
men and 3299 women) and the subjects were between 30 and 79 years of age. 
Concentration lower than 20 nmol/l was said to indicate vitamin D deficiency and 
concentration between 20 and 37.5 nmol/l was to indicate moderate hypovitaminosis D. 
Serum 25(OH)D (S-25(OH)D) status was measured by Radioimmunoassay (RIA). The 
seasonal variation was taken into account by considering the period August-October to 
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represent autumn and November-March to represented winter. The mean concentration 
for men was 45.1 ± 0.53 (range 5-132) nmol/l and for women 45.2 ± 0.46 (7-143) 
nmol/l. Hypovitaminosis D was more common in the subjects examined in the winter 
than in those examined in autumn. Moderate hypovitaminosis D was found in 42.2% of 
men and 39.4% of women examined in the winter. Vitamin D deficiency was found in 
5.2% and 3.4% respectively. In the autumn period the numbers dropped to 25.2% and 
2.7% for men and 28.2% and 2.9% for women. Low S-25(OH)D was common and 
correlated with low BUA and SOS values. Low S-25(OH)D was also related to higher 
body fat mass. 
 The relationship between S-25(OH)D and risk of stress fractures was studied by 
Välimäki et al. (2005). The study consisted of 179 Finnish military recruits who were 
aged between 18 and 20 years. Of those 15 experienced a stress fracture during military 
service. The rest was considered to be the control group. S-25(OH)D was measured 
with RIA. Concentration lower than 20 nmol/l indicated vitamin D deficiency and 
concentrations below 37.5 nmol/l indicated hypovitaminosis D. The S-25(OH)D was 
measured once during summer and once during winter. The mean concentration for 
stress facture subjects was 44 (range 26-64) nmol/l and for none-stress facture also 44 
(18-107) nmol/l. Vitamin D deficiency was common in the wintertime when 39% of all 
men had it. Hypovitaminosis D was recognized in 95% of all subjects in the winter. In 
the  summer  prevalence  of  vitamin  D  deficiency  was  only  1%  to  2%  and  that  of  
hypovitaminosis D 27% to 30%. Low S-25(OH) was common but not related to stress 
fracture incident. 
 The S-25(OH)D concentrations in healthy subjects from the Helsinki-Vantaa 
region and Turku-Loimaa region (both ~60ºN) were analyzed in 2001 (Lamberg-Allardt 
et al., 2001). Samples were taken in March 1998. The aim of the study was to determine 
if recommended vitamin D intake (5µg/d) lead to a sufficient vitamin D status. Data was 
obtained from 202 women and 126 men aged between 31 and 43 years. Deficiency was 
determined by two different aspects. S-25(OH)D concentration below 25 nmol/l was 
considered to indicate vitamin D deficiency. On the other hand the S-25(OH)D 
concentration where serum intact parathyroid hormone (S-iPTH) began to rise was 
considered to indicate insufficiency. S-25(OH)D concentrations were measured by RIA. 
Based on the first consideration for vitamin D deficiency 26.2% of the women and 
28.6% of the men represented this status. Based on the relation between S-25(OH)D and 
S-iPTH (80 nmol/l in women and 40 nmol/l in men) 86% of the women and 56% of the 
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men had insufficient vitamin D status. Vitamin D status was low in a big part of the 
study population even when vitamin D intake met the recommendations. 
 Five different Finnish studies were analyzed for vitamin D status in the study of 
Lamberg-Allardt and Viljakainen (2006). The overall amount of serum samples was 
nearly 1500. The aim was to investigate if vitamin D status had improved from 2002 to 
2004 due to new fortification of liquid dairy products. All measurements were done 
with  the  enzyme  immunoassay  (EIA).  Subjects  were  from  the  study  Type  1  Diabetes  
Prediction and Prevention (DIPP) (n=107), the intervention project for coronary heart 
disease risk factors (STRIP) (n=101), the girl-cohort for calcium and vitamin D 
intervention (CALEX) (n=100), the FINRISK study (n=249) and the OPTIFORD study 
(n=100). In the end 634 subjects in 2002 and 630 subjects in 2004 were analyzed. 
Vitamin D insufficiency was characterized as S-25(OH)D concentration below 50 
nmol/l and concentrations between 50 and 79.9 nmol/l were considered to be sufficient. 
Concentrations above 80 nmol/l were considered to be optimal. In 2002 37.7% of all 
subjects had insufficient vitamin D status whereas the amount was 21.3% in 2004. The 
amount of sufficient status subjects was respectively 38.1% and 36.7%. The amount of 
optimal status subjects grew the most from 24.3% to 41.7%. The study subjects were 
not optimal to reflect the normal Finnish population, due to vitamin D supplement use 
and healthier food consumption. 
 Välimäki et al. (2004) wanted to assess the prevalence of vitamin D deficiency 
and the connection between this and peak bone mass in young Finnish men. The 
subjects were between 18.3 and 20.6 years old and the number of subjects was 220. 
Vitamin D measurement was done once in the summer (July 2000 n=220), once in the 
winter (January 2001 n=167) and again in the summer (July 2001 n=94). Vitamin D 
deficiency was defined as a concentration ?20 nmol/l. Measurement of S-25(OH)D 
concentration was done with RIA. In July 2000 only 0.9% of subjects had vitamin D 
deficiency. The mean concentration was 44 (15-107) nmol/l. In January 2001 38.9% of 
the subjects suffered from vitamin D deficiency. There the mean concentration was 24 
(6.0-66) nmol/l. When subjects were analysed six months later in the summer again 
only 2.1% had vitamin D deficiency and the mean concentration was 41 (18-72) nmol/l. 
They suggested that vitamin D deficiency may be detrimental to acquisition of maximal 
peak bone mass. 
 The vitamin D status of Finnish pregnant women was assessed in 1984 by 
Lamberg-Allardt et al. (1984). They measured the S-25(OH)D concentration from the 
maternal and cord blood at delivery with a competitive protein binding assay. They 
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studied 192 mothers of which 99 received a 12,5 µg/d supplement. The measurement 
time periods were summer (June-August) and autumn (September-November). Their 
results showed that there was a clear variation between S-25(OH)D concentration 
means in the summer and autumn in the supplemented and not supplemented group (75 
nmol/l vs. 52 nmol/l and 103 nmol/l vs. 73 nmol/l). It became clear that the S-25(OH)D 
concentration means were lower in the cord blood samples than the maternal blood 
samples (46 nmol/l vs. 59 nmol/l and 60 nmol/l vs. 87 nmol/l for both groups 
respectively). 
 The studies of Kauppi et al. (2009), Välimäki et al. (2005), Lamberg-Allardt et 
al. (2001) and Välimäki et al. (2004) are summarized in Table 6 for their good 
comparability.  As  a  conclusion  it  can  be  said  that  vitamin  D  status  in  the  healthy  
Finnish population is generally low which is mostly due to the short period of UVB 
light exposure. 
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Table 6. Vitamin D status in the healthy Finnish population. 
Cases     Controls     Method CV % (mean)  Conclusion Reference 
Subjects Age (mean) Number Sex 
S-25(OH)D 
(nmol/l) 
(Mean) 
Subjects Age (mean) Number Sex 
S-
25(OH)D 
(nmol/l) 
mean 
 intra-assay 
inter-
assay   
Healthy adults 54.5 (30-79) 
2736 Male 45.1 
 RIA (Incstar*) 3.5 6.9 
low S-25(OH)D concentrations were 
associated with (BUA) and (SOS) 
Kauppi et al., 
2009 
3299 Female 45.2 
Stress fractured 
military recruits 
19 (18-
20) 15 Male 44 
Not stress 
fractured 
military 
recruits 
19 (18-
20) 164 Male 44 
RIA 
(Diasorin) 8.9 12.8 
S-25(OH)D concentrations not lower in 
stressed subjects 
Välimäki et 
al., 2005 
Young men 
baseline (July) 
19.6 
(18.3-
20.6) 
220 Male 
44 
 RIA (Diasorin) 7.4 10.8 
almost 40% of the subjects had vitamin d 
deficiency during the winter, S-25(OH)D 
concentration correlated positively with bone 
mineral content 
Välimäki et 
al., 2004 
Young men 6 
months from 
baseline (winter) 
24 
Young men 12 
months from 
baseline 
41 
Healthy adults 
38 202 Female 47 
 RIA (Incstar) 10.1 14.9 
86% of women and 56% of men had 
insufficient vitamin d status (based on the 
relation to S-iPTH) 
Lamberg-
Allardt et al., 
2001 37 126 Male 45 
 
 
*Diasorin was formerly known as Incstar 
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1.1.7 Vitamin D status and disease in the Finnish population 
 Toriola et al. (2010) performed a study where the relation between S-25(OH)D and risk 
for ovarian cancer was assessed. Finnish subjects were diagnosed with ovarian cancer 
10 years after serum sampling and the number was 201. Two control sets were matched 
to subjects, one for age, parity and sampling season (± 4 weeks) (always 2 per subject n 
= 398) and one for age, parity and opposite sampling season (6 months ± 4 weeks) (n = 
199). The age raged from 17.5 to 44 years. The S-25(OH)D was measured with RIA. S-
25(OH)D below 50 nmol/l was considered to indicate vitamin D deficiency, 50-75 
nmol/l was considered to indicate insufficient status and concentration above 75 nmol/l 
were to indicate sufficient status. Median values for cases, same season controls and 
opposite season controls were 35.0, 35.8 and 34.3 nmol/l respectively. Sufficient status 
was observed in 4 cases of 200 and 21 of 398 controls. Insufficient status was very 
common both in cases and controls. 
The connection between vitamin D status and breast cancer or pregnancy 
induced breast cancer (PABC) has been studied in Finland (Agborsangaya et al., 2010). 
The study subjects were identified from the Finnish Cancer Registry and samples were 
drawn from the Finnish Maternity Cohort for both cases and controls. Breast cancer 
patients with at least two singleton pregnancies were selected. The sample size of breast 
cancer  patients  (follow-up  time  ?10  years)  was  100  and  the  same  amount  of  controls  
was matched to them for blood withdrawal time and year (±1) (summer=May-August, 
winter=December-March), age at sampling and parity (±1). The number of PABC cases 
was  111  and  the  same  amount  of  controls  was  matched  for  age  (±1),  parity  (±1)  and  
date of blood sampling (±15 d). The S-25(OH)D concentration was measured with RIA. 
The concentration results were divided into quintiles (breast cancer 1. pregnancy: ?27.5, 
27.6-37.5, 37.6-48.5, 48.6-55.5, ?61.6 nmol/l, 2. pregnancy: ?27.8, 27.9-36.9, 37.0-
46.5, 46.6-55.5, ?56.6 nmol/l and PABC: ?25.8, 25.9-34.9, 35.0-44.7, 44.8-64.0, ?64.1 
nmol/l). They considered that conducting to their results vitamin D concentration was 
not associated to breast cancer in general. Interestingly they considered higher (2nd to 5th 
quintiles compared to lowest quintile) vitamin D concentrations to be a risk for PABC. 
The relation between S-25(OH)D and acute myocardial infarction (AMI) and 
stroke in elderly subjects from the city of Turku and surrounding areas in southwestern 
Finland was investigated by Marniemi et al. (2005). The age ranged between 65 and 99 
years. The study was a 10-year follow-up. The AMI group consisted of 65 men and 65 
women, and the stroke group consisted of 34 men and 36 women. The control group for 
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the AMI group consisted of 255 men and 304 women who had experienced no coronary 
event. The control group for the stroke cases consisted of 282 men and 308 women with 
similar characteristics. The S-25(OH)D concentration was measured by RIA. The mean 
± standard deviation (SD) S-25(OH)D concentration for AMI and stroke cases were 
28.4 ± 17.0 and 29.6 ± 17.9 nmol/l. The results for the respective control groups were 
30.7 ± 19.7 and 31.3 ± 19.4 nmol/l. S-25(OH)D concentration was lower in the case-
groups than in the control groups.  
Nurmi et al. (2005) studied the concentration of S-25(OH)D in southeastern 
Finnish hip fracture patients. Cases were recognized from two Finnish hospitals and the 
number was 223. Both men (n=65) and women (n=158) took part in the study. Age 
varied from 47-96 in women and 38-91 in men. The cases were divided into groups 
depending on place of residence (actual home, residential home or institution). The 
seasonal variation of S-25(OH)D concentration was followed. Measurement was done 
by RIA. Severe vitamin D deficiency was defined as a concentration <20 nmol/l and 
moderate vitamin D deficiency as a concentration between 20 and 37.4 nmol/l. Out of 
all patients 52% of women and 55% of men suffered from moderate vitamin D 
deficiency. In 9% of all patients vitamin D deficiency was severe. Only 3% of all 
patients had vitamin D concentrations above 74 nmol/l. The mean concentration among 
women was 38.1 nmol/l and among men 37 nmol/l. Concentrations were lower in 
patients living in a residential home or institution than patients living at home, 55%, 
61% and 50% respectively. 
The amount of vitamin D deficiency in in- and outpatients in the capital region 
of Finland was assessed in 2001 (Kauppinen-Mäkelin et al. 2001). Inpatients consisted 
of 57 women and 49 men who were between 45 and 58 years. Outpatients consisted of 
48 women and 51 men with the age range of 42 to 46 years. Measurement was done in 
October 1998 (31 inpatients were reanalysed in March or April 1999). The method used 
to determine S-25(OH)D was RIA. Severe vitamin D deficiency was considered to be 
the case when patients had S-25(OH)D concentrations below 20 nmol/l. When S-
25(OH)D  concentration  was  50  nmol/l  or  less  S-iPTH  concentration  began  to  rise  
(hypovitaminosis D). Overall 61% of male hospital patients had S-25(OH)D 
concentrations ?37.5 nmol/l. The amount of female hospital patients who had the 
preceding concentration was 70%. When outpatients where considered the amounts 
were 37 and 44% respectively. Severe vitamin D deficiency was found in 20% of male 
inpatients and 26% of female inpatients. The amounts for outpatients were 6% and 2% 
respectively.  
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In conclusion it can be noted that the vitamin D status generally in different 
disease groups is low. Low vitamin D was observed in all studies, but it was not 
necessarily associated to the disease when compared with controls. There are 
suggestions that low vitamin D status can be associated to heart conditions and 
institutional care. The latter is obviously due to absence of sunlight exposure.    
1.2 Type 1 Diabetes mellitus 
1.2.1 T1D pathogenesis and genetics 
T1D  is  caused  by  the  autoimmune  destruction  of  the  beta-cells  in  the  pancreas.   The  
beta-cells in the islets of Langerhans are infiltrated by dendritic cells, macrophages and 
T lymphocytes. Usually onset of the disease is at young age from 1 year old to 18 year 
olds (see Pociot and McDermott, 2002).  
The autoimmune process is characterised by specific autoantibodies developed 
against T1D antigens in the beta-cells (Wenzlau et al., 2007). According to Ounissi-
Benkalha et al., (2008) and Atkinson and Eisenbarth (2001) the main autoantibodies are 
insulin autoantibody (IAA), islet cytoplasmic autoantibody (ICA), glutamate 
decarboxylase antibody (GADA), insulin autoantigen 2 (IA2) and islet cell autoantibody 
512/protein tyrosine phosphatase IA2 (ICA512/IA2A). Wenzlau et al. (2007) described 
another autoantibody in 2007; a zinc transporter antibody (ZnTA). According to 
Eisenbarth (1986) the development of T1D is divided into six stages. The disease begins 
with the first stage; the genetic susceptibility. Some genetically susceptible individuals 
develop active autoimmunity (stage 3) through a hypothetical triggering event (stage 2). 
Stage four is characterised as a condition where blood glucose level is still normal but 
insulin secretion is progressively lost. During stage five some insulin is still secreted but 
it is followed by stage six; the complete destruction of beta-cells in the pancreas. 
 T1D  is  a  complex  autoimmune  disease  with  inheritance  related  and  
environmental features. The most important chromosomal regions associated to T1D are 
the human leukocyte antigen (HLA) region at chromosome 6p21.3 and the insulin (INS) 
gene region at 11p15.5 (see Pociot and McDermott, 2002). These regions have been 
named IDDM1 and IDDM2, where IDDM1 is localised in the major histocompability 
complex  (MHC) on  6p21 consisting  of  at  least  HLA-DQB1 and  HLA-DRB1 loci  and  
probably also HLA-DPB1 (Cox et al., 2001). The genes of the MHC are divided into 
four  classes  I,  II,  III  and  IV  and  the  strongest  association  to  T1D  risk  has  been  
connected with class II genes (see Pociot and McDermott, 2002). HLA related 
  
37
susceptibility may account for less than 50% of the inherited disease risk according to 
Pociot and McDermott (2002). IDDM2 susceptible loci is a variable number of tandem 
repeats (VNTR) which consists of a repetition of 14-15 bp oligonucleotide sequence and 
can be repeated 26 to 200 times (see Pociot and McDermott, 2002). The VNTR alleles 
are divided into three classes (I, II, and III) which vary in repeat size from 26 to 63, 
mean of 80 and 141 to 209 repeats, where strongest association to increased T1D risk 
has been for class I alleles and protective association has been linked to class III alleles 
(reviewed by Pociot and McDermott, 2002). About 20 non-HLA genomic intervals with 
linkage evidence to T1D have been discovered in different studies but only the function 
of IDDM2 and IDDM12 has been identified (reviewed by Pociot and McDermott, 2002, 
Atkinson and Eisenbarth, 2001). IDDM12 is located on chromosome 2q33 and 
apparently has some effect on the cytotoxic T-lymphocyte-associated protein 4 (CTLA-
4) which has an effect in the modulation of immune responsiveness (Nistico et al., 
1996).   
 No environmental factor has been identified to have an indefinite effect on T1D 
development (see Atkinson and Eisenbarth, 2001). The main environmental factors that 
have been suggested to affect the T1D risk incidence are divided into three groups: viral 
infections (for example coxsackievirus and cytomegalovirus), early infant diet (the 
relation of breast feeding versus early introduction of cow`s milk) and toxins (like N-
nitroso derivatives) (reviewed by Atkinson and Eisenbarth, 2001). Other factors 
suggested are vaccine administration, psychological stress and climatic influences and 
environmental factors. These are believed to serve as modifiers rather than disease 
pathogenesis triggers (see Atkinson and Eisenbarth, 2001). Findings that multiple 
infections  during  the  first  years  of  life  are  associated  to  a  decreased  risk  of  T1D  
somehow explain the rapid growing prevalence in a world where sanitation, health care 
access and vaccination have improved. 
1.2.2 Prevalence and trend in Finland 
Harjutsalo et al. (2008) studied the prevalence of T1D between 1980 and 2005 in 
Finland. The number of T1D cases diagnosed before the age of 15 was 10737 (5816 
boys and 4921 girls). The number of incidence grew from 31.4/100 000 per year in 
1980 to 64.2/100 000 per year in 2005. The predicted number for new cases between 
2006 and 2020 was 10 800 according to Harjutsalo et al. (2008). The trend from 1965 to 
2005 is illustrated in Figure 9. 
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Figure 9. The number of T1D incidents in Finland between 1965-2005 (Harjutsalo, 2007). 
1.3 Vitamin D and Type 1 Diabetes 
Vitamin D and T1D have been linked together due to the fact that there is a 
geographical variation in T1D prevalence and vitamin D synthesis in the skin. Both 
environmental and genetic factors have been studied. Insulin secretion is dependent on 
vitamin D status. Vitamin D deficiency reduces secretion of insulin directly and 
indirectly by increasing intracellular calcium which decreases insulin secretion 
(Penckofer  et  al.,  2009).  Vitamin  D  may  reduce  the  risk  of  infections  that  can  be  
associated to autoimmune process of beta-cell destruction and vitamin D may directly 
reduce the autoimmune process of beta-cell destruction (see Holick, 2008). Vitamin D 
deficiency increases insulin resistance via TNF-? (Boucher, 1998). 
 Maternal vitamin D deficiency and its role on foetal development have been 
assessed in different studies. In the study of Fronzak et al. (2003) low maternal vitamin 
D intake via food was associated to higher risk in islet autoimmunity in the offspring. 
Stene et al. (2000) concluded that the maternal intake of cod liver oil reduced the risk of 
the offspring to develop T1D either due to vitamin D or the n-3 fatty acids 
eicosapentaenoic acid or docosahexaenoic acid. No study has been conducted before 
where the maternal S-25(OH)D status has been assessed and connected to T1D 
development in the offspring to my knowledge.  
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1.3.1 Genetic association between vitamin D and Type 1 Diabetes 
The reason that there is a seasonal variation (more incidents in autumn and winter 
months) and a geographical gradient (more incidents in the north) in T1D diagnosis 
suggests that sunshine and T1D are connected. The genetic associations between T1D 
and vitamin D have therefore been investigated. Bailey et al. (2007) showed that gene 
polymorphisms in CYP27B1 (gene that codes for vitamin D 1?-hydroxylase) are 
associated to T1D. They identified the polymorphisms as -1260 and +2838. They did 
not find any other T1D associated vitamin D related genes in their study. VDR receptor 
polymorphisms have been associated to T1D (see Zella and DeLuca, 2003). One is 
associated with glucose intolerance and another with insulin resistance. Four common 
VDR variants have been described (see Zella and DeLuca, 2003). They differ in their 
restriction enzyme sites (FokI, BsmI, ApaI and TaqI sites, polymorphisms at exon 2, 
intron between exon 8 and 9 and exon 9). The BsmI restriction site alleles have been 
associated to T1D susceptibility in Indian Asian, Taiwanese and German populations 
whereas the FokI restriction site alleles have been associated to Japanese T1D 
populations (see Zella and DeLuca, 2003). 
1.3.2 Animal studies 
Mathieu et al. (1994) showed in their study that 1,25(OH)?D treatment prevented the 
development of clinical diabetes in none-obese diabetic (NOD) mice which serve as an 
animal model for human autoimmune diabetes. Mice were fed with 5 ?g 1,25(OH)?D? 
per kg twice a day for 200 days. This led in the significant reduction of insulitis, a 
leukocytic infiltration of the pancreatic islets, which leads to development of diabetes. 
The mechanism by which 1,25(OH)?D? affects this is not quite clear. Mathieu et al. 
(1994) suggested that due to the fact that 1,25(OH)?D? inhibits effector T-cell 
proliferation and lymphokine (especially IL-2, IFN-? and TNF-?) production, stimulates 
monocyte differentiation, macrophage function and suppressor function in vitro, it 
probably restores the defective suppressor mechanisms in NOD mice (Bhalla et al., 
1984, Rigby et al., 1987, Reichel et al., 1987, Meehan et al., 1992). They also concluded 
that the problem with 1,25(OH)?D? when used in vivo, is  the major effect  on calcium 
metabolism. The case mice did not develop hypercalcaemia, but the effect was seen on 
bone turnover markers. Mathieu et al. (1994) therefore suggested that the treatment 
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should be done with an analogue of 1,25(OH)?D? which has decreased effects on 
calcium metabolism. 
 NOD mice were partially protected from diabetes by sufficient vitamin D status 
alone in one study (Zella et al., 2003). There 88% of vitamin D deficient female mice 
were diabetic at 200 d age, whereas only 46% of vitamin D sufficient female mice were 
diabetic by the same time. In the male mice the amounts were 44% and 0% respectively. 
Zella et al. (2003) also reported the onset of diabetes much earlier in vitamin D deficient 
mice than in vitamin D sufficient mice. Additionally they found that mice that where 
fed 50 ng 1,25(OH)?D? per day were completely protected from diabetes regardless of 
vitamin D status. They studied if a dose of 10 or 20 ng would be enough but received no 
or only partial positive results. 
 The effect of early life vitamin D deficiency on diabetes onset in NOD mice by 
breeding test mice parents and test mice in a ultra-violet free environment and feeding 
them with vitamin D depleted diet for 100 days was studied by Giulietti et al. (2004). 
All mice were followed 250 days when 35% of male vitamin D deficient mice and 66% 
of female vitamin D deficient mice were diabetic compared to 15% and 45% of the 
control mice. They showed that at 100 days, more vitamin D deficient mice were 
glucose  intolerant  than  control  mice.  The  IL-1  concentration  in  islets  of  vitamin  D  
deficient mice was higher and the cytokine profile of their peritoneal macrophages was 
abnormal, showing low IL-1 and IL-6, and high IL-15 concentrations. The vitamin D 
deficient mice also had lower concentrations of L-selectin expressing T-lymphocyte 
(CD4+CD62L+) cells in their thymus and lymph nodes. Giulietti et al. (2004) 
concluded that the disturbed cytokine profile might contribute to the earlier beta-cell 
destruction in NOD mice. 
 In conclusion, it has been shown that development of T1D in NOD mice has 
been prevented with either vitamin D metabolite supplementation or sufficient vitamin 
D status alone. 
1.3.3 Human studies 
1.3.3.1 Maternal vitamin D intake and status 
The study of Maghbooli et al. (2007) showed that there is a relation between vitamin D 
deficiency and insulin resistance in GDM patients. They studied 741 pregnant women 
of which 52 developed GDM. Severe vitamin D deficiency (<12.5 nmol/l) was more 
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common in GDM patients than in normoglycaemic pregnancies. The insulin resistance 
was calculated by this formula: 
 
IShoma= (FPG*FPI)/22.5 
 
where FPG=fasting plasma glucose and FPI=fasting plasma insulin. Homeostatic model 
assessment index (HOMA index) values below 3.0 are normal and show no sign of 
insulin resistance. The HOMA values were significantly higher in GDM patients. The 
25(OH)D  measurements  where  done  with  RIA.  They  defined  25(OH)D  statuses  as  
severe deficiency when the concentration was <12.5 nmol/l, moderate deficiency when 
it was between 12.5-24.9 nmol/l, mild deficiency when it was between 25-34.9 nmol/l 
and normal when it was above 34.9 nmol/l. Their results showed that 70.6% of all 
participants had vitamin D deficiency (<25 nmol/l). Insulin resistance was higher in 
vitamin D deficient participants. 
 One study investigated if maternal dietary vitamin D intake had influence on 
islet autoimmunity (IA) in offspring (Fronczak et al., 2003). The results suggested that 
vitamin D through food during pregnancy may have a protective effect on the 
appearance of IA in the offspring. The intake of vitamin D was evaluated from the third 
trimester of pregnancy with a questionnaire (Willet Food Frequency Questionnaire 
(FFQ)). The number of subjects was 233. Mothers with T1D children were identified 
through the Diabetes Autoimmunity Study in the Young (DAISY). Children were 
recruited to DAISY by screening for diabetes-susceptibility HLA-alleles from all 
children born in the St. Joseph Hospital in Denver, Colorado or through identifying 
first-degree relatives with T1D. The interesting results showed that vitamin D intake via 
supplements was not related to a protective effect on IA in the offspring, only vitamin D 
through food. 
 The effect of maternal intake of cod liver oil or multivitamin administration on 
T1D development in the offspring was studied by Stene et al. (2000). The results were 
obtained by a questionnaire. The study population consisted of 85 diabetic participants 
and 1071 control subjects. The diabetic subjects were identified from the Norwegian 
National Childhood Diabetes Registry and living in the county of Vest-Agder. Patients 
born between 1982 and 1998 were selected. Controls were selected randomly from the 
official  population  register  of  the  county.  Results  showed  that  maternal  intake  of  cod  
liver oil strongly correlated negatively with the risk of T1D in the children. They found 
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out that there was no significant association between maternal multivitamin 
administration and risk of T1D in the child. 
 To conclude, it can be said that vitamin D deficiency during pregnancy was 
associated to insulin resistance in GDM patients. It seems that maternal vitamin D 
intake via food or cod liver oil has a risk lowering effect on T1D development in the 
offspring whereas vitamin D intake through supplements or multivitamins has no effect 
on T1D development.    
1.3.3.2 Early life vitamin D intake and status 
The EURODIAB Substudy 2 (1999) investigated the association of early life vitamin D 
intake with the risk of T1D in seven European study centres (Austria, Bulgaria, Latvia, 
Lithuania, Luxembourg, Romania and Northern Ireland). They collected the results with 
questionnaires and interviews. The study population consisted of 746 diabetic 
participants and 2188 control subjects. They conducted that there was a clear negative 
correlation between vitamin D intake during infancy and risk of diabetes. 
 The relation between cod liver oil intake in the first year of life or during 
maternity and risk of T1D was assessed by Stene et al., 2003. Children diagnosed with 
T1D between 1997 and 2000 and born between 1985 and 1999 were selected and the 
number of participants was 545 patients. The control subjects were randomly selected 
but they had to be born in the same time of year. The number of controls was 1668. The 
results were obtained by questionnaire addressed to the mother. In contrast to their study 
in 2000, they concluded that the maternal cod liver oil intake had no effect on the risk of 
T1D in the offspring. On the other hand they found out that the intake during first year 
of life was associated to lower risk of T1D. 
 The study of Hyppönen et al. (2001) was conducted to assess the relation 
between early-life vitamin D intake and risk of T1D. The study population was 
conducted of children who were born in Oulu and Lapland during 1966. 10 821 children 
were followed up until end of 1997 for the possibility of T1D development. Of these 
10 821, 81 children were diagnosed with diabetes. The vitamin D supplementation and 
frequency of rickets was obtained by questionnaires to the mothers. The study resulted 
that the development of T1D was associated with low vitamin D intake and rickets 
during the first year of life. The vitamin D recommendations just changed in 1964 when 
the dose was reduced from 4000-5000 IU (100-125 ?g) to 2000 IU (50 ?g). 
 Differences in vitamin D status between T1D children and non-diabetic children 
were investigated in Qatar (Bener et al., 2009). The study population consisted of 170 
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T1D and control subjects below 16 years. The study was conducted during a period 
between August and December 2007. Bener et al. (2009) defined that vitamin D 
deficiency was a condition with serum 25(OH)D levels below 30 ng/ml (75 nmol/l) and 
an optimal status was obtained with concentrations between 30 and 80 ng/ml (75 nmol/ 
and  200  nmol/l).  The  concentration  of  S-25(OH)D  was  measured  with  RIA.  Their  
results showed that vitamin D deficiency was higher in T1D children (90.6%) than in 
healthy children (85.3%) although the prevalence was high in both groups. They also 
studied by questionnaire if vitamin D supplementation along with breast feeding was 
associated to lower T1D risk. They found out that vitamin D supplementation was poor 
in both groups (46.5% and 51.8%) and again a little poorer in the T1D group. The 
people in Qatar cover their whole body with clothing except their faces. 
 Svoren et al. (2009) studied the vitamin D status in young adults with T1D in 
the North-eastern United States. The subjects were identified from the Joslin Diabetes 
Centre, Boston and 128 T1D subjects participated in the study. S-25(OH)D was 
measured with RIA. They defined the concentration ?30 ng/ml (75 nmol/l) to indicate 
sufficient status, 21 to 29 ng/ml (52.5-72.5 nmol/l) to indicate insufficient status and 
?20 ng/ml (?50 nmol/l) to indicate deficient status. Their results showed that 61% had 
insufficient S-25(OH)D status, 15% deficient and 24% sufficient status. Similar results 
were found in the study of Pozzilli et al. (2005) where they studied the S-25(OH)D 
status differences in newly diagnosed T1D patients and healthy controls in the Lazio 
region in Italy. The S-25(OH)D concentrations were significantly lower in the T1D 
group than in the control group. 
 Greer et al. (2007) studied the same hypothesis in Queensland, Australia. Their 
study consisted of 47 T1D subjects and 94 control subjects. The S-25(OH)D 
concentration was measured by RIA. The concentration they determined to indicate 
vitamin D deficiency was ?50 nmol/l. The amount of vitamin D deficient patients was 
significantly higher in the T1D group (43%) than in the control group (18%). Samples 
were stored samples which were taken at any time of the year. 
 To conclude, vitamin D intake during early life can be associated to lower risk 
of T1D development later in life based on data obtained from questionnaires. This data 
however is considered not to be highly reliable due to difficulties in remembering 
vitamin D intake from years ago. Another aspect which can be concluded, is the fact 
that S-25(OH)D concentrations are lower in young T1D subjects when compared with 
healthy subjects. 
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1.3.3.3 Vitamin D status in adults 
In 2006 one study investigated if plasma 25(OH)D levels were lower in young adult 
T1D subjects than controls in Sweden (Littorin et al., 2006). The subjects were 
identified from the Diabetes Incidence Study in Sweden (DISS) during 1987-1988. The 
number of T1D patients was 138 and the number of controls was 208. The 25(OH)D 
concentration was measured by the Nichols Advantage 25OHD assay. The mean 
concentration of 25(OH)D was lower in T1D patients than controls (82.5 vs. 96.7 
nmol/l). After a 8-year follow-up the concentrations were lower when the whole study 
population was considered (86.3 vs. 81.5 nmol/l). Littorin et al. (2006) also showed that 
the 25(OH)D concentration was significantly lower in diabetic men than women (77.9 
vs. 90.1 nmol/l). 
 Borissova et al. (2003) showed that treating T2D patients with vitamin D? (1332 
IU=33.3 µg daily for one month) increased first phase insulin secretion by 34.3%. Ten 
T2D women served as patients and 17 healthy women as controls. At baseline 70% of 
the patients were deficient in 25(OH)D concentration whereas 70% had sufficient status 
after treatment. 
 The possibility that subjects with hypovitaminosis D are at higher risk for 
insulin resistance and metabolic syndrome was investigated by Chiu et al. (2004). They 
studied 126 healthy glucose-tolerant subjects in Los Angeles, United States, for 
25(OH)D concentration, glucose-concentration and insulin sensitivity. The results 
showed that 47 subjects had 25(OH)D concentrations below 20 ng/ml (50 nmol/l). Low 
25(OH)D concentration was associated with higher 60-, 90-, and 120-min post 
challenge plasma glucose-concentrations. A positive correlation was found between 
25(OH)D concentration and insulin sensitivity index (ISI). They concluded that low 
25(OH)D concentration must therefore have an effect on beta-cell function and insulin 
response. They found that 30% of the hypovitaminosis D subjects were at risk for 
metabolic syndrome whereas the amount was only 11% in the non-hypovitaminosis D 
subjects. 
 Bierschenk et al. (2009) compared the S-25(OH)D status in 415 study subjects. 
The amount of healthy controls was 153, new-onset T1D subjects 46, established T1D 
subjects (samples ?5 months from diagnosis) 110 and first-degree relatives of the 
diabetic patients 106. The age ranged considering all groups from 1.0 to 65.1 years. The 
study was conducted in a solar-rich environment in Florida, United States. Measurement 
was done with an EIA. Vitamin D deficiency was defined as a concentration ?20 ng/l 
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(50 nmol/l), insufficiency as 21-30 ng/ml (52.5-75 nmol/l) and sufficiency as >30 ng/l 
(>75 nmol/l). Even though their study was conducted in a solar-rich environment mean 
S-25(OH)D concentrations in all groups were under a sufficient (>30 ng/l/75 nmol/l) 
concentration. The groups did not differ significantly in their S-25(OH)D 
concentrations. The concentrations ranged in healthy controls between 13.0 and 37.4 
ng/ml (32.5-93.5 nmol/l), in new-onset T1D patients between 12.2 and 30.2 ng/l (30.5-
60.4 nmol/l), established T1D patients between 13.8 and 33.9 ng/l (34.5-84.8 nmol/l) 
and first-degree relatives between 12.7 and 33.1 ng/ml (31.8-82.8 nmol/l). The group of 
new-onset T1D patients had little lower concentrations than the other groups but not in a 
significant amount. 
To conclude the vitamin D status in adults, it can be said, that some studies 
showed lower S-25(OH)D concentrations in T1D subjects when compared to controls 
and  others  did  not  show  differences  between  T1D  and  control  subjects.  Lower  S-
25(OH)D concentration was interestingly found in T1D men than women. It can also be 
concluded that vitamin D status can be associated to T2D, where sufficient vitamin D 
status can prevent insulin resistance and metabolic syndrome. Vitamin D 
supplementation can also enhance insulin secretion. 
1.4 Vitamin D Measurement methods 
1.4.1 Different methodology 
For a laboratory measuring 25(OH)D it is highly important to participate in the 
International Quality Assessment Scheme for Vitamin D metabolites (DEQAS) survey 
(described in 1.4.2) for accurate measurement data. Circulating 25(OH)D is very stable 
when stored in plasma or serum. Hollis (2008) reported that his laboratory has used 
same pooled human 25(OH)D internal controls for over 10 years stored at -20 ºC. They 
noticed none detectable degradation of the compound in the samples during that time. 
The samples provided by the DEQAS are also shipped by ground post to participants 
and no degradation has been seen there either. Wielders and Wijnberg (2008) reported 
their  results  on  25(OH)D  stability  in  2008.  They  showed  that  a  mean  decrease  of  
25(OH)D concentration of 2.3% was seen when whole blood samples were left  on the 
bench for 72 h. When serum samples were left on the bench a mean decrease of 3.4% 
(24 h) and 8.5% (7 d) was observed. About same results were obtained when serum 
samples were left on the bench in the dark (4.5% and 8.1%). After 7 days of storage in 
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the refrigerator mean decrease of 1.8% was measured. Wielders and Wijnberg (2008) 
also tested the effect of repeated freeze-thaw cycles. After 4 cycles of freeze-thawing 
the mean increase of 25(OH)D concentrations was 2.6%. The cis-triene structure of 
25(OH)D is responsible for the molecules possible oxidation, UV induced 
conformational changes, heat-induced conformational changes and possibility of attacks 
by free radicals (Hollis, 2008). Hollis (2008) made an experiment where he exposed 
crystalline  25(OH)D  in  ethanol  on  an  open  Petri  dish  to  UV  light.  The  molecule  was  
destroyed in a few minutes. When the molecule was exposed to UV light in serum or 
plasma there was no degradation detected after 2 days of UV exposure. Two reasons for 
this could be that first UV light penetrates aqueous liquids poorly and second vitamin D 
and its metabolites are mostly bond to DBP or other proteins in serum and plasma. This 
complex seems to protect the degradation of 25(OH)D.  
It is important to find simple, high-throughput methods for measuring 25(OH)D 
from patient samples because of the rising need in diagnosing vitamin D deficiency, and 
other vitamin D related metabolic statuses (Wagner et al., 2009). Vitamin D nutritional 
status (represented by the serum/plasma status of 25(OH)D)) is important for 
monitoring bone health and vitamin D deficiency and intoxication. It is also important 
for diagnosing rickets, secondary hyperparathyroidism and osteoporotic fracture (see 
Kimball and Vieth, 2007). Vitamin D nutritional status is measured by determining the 
serum concentration of 25(OH)D. In all species where the conversion of vitamin D to 
25(OH)D has been  measured the change has been rapid. 25(OH)D has a much longer 
shelf-life than vitamin D and is therefore a good metabolite to measure vitamin D 
nutritional status (see Bouillion et al., 1998).  
When vitamin D wants to be measured different approaches are used to define 
vitamin adequate and insufficient status. The relation between 25(OH)D and PTH can 
be studied to find some 25(OH)D concentrations where PTH concentrations begin to 
rise over appropriate healthy level. The optimal 25(OH)D concentration for optimal 
intestinal  absorption  of  calcium  can  be  estimated  and  studied  or  the  relation  between  
25(OH)D concentrations and frequency of various diseases can be the site of interest. 
On the other had studying the relation of mean concentrations of 25(OH)D and positive 
effects,  like  disease  prevention  can  be  the  sight  of  aspect  (Cavalier  et  al.,  2009).  As  
mentioned before the measuring of vitamin D is challenging. The most difficult 
problems of the molecule are that it is strongly bound to binding protein (DBP or other) 
in the blood, that it is present in low (nanomolar) concentrations, and in two different 
forms (D? and  D?) (Wagner et al., 2009). The particular molecule 25(OH)D is 
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challenging to measure because of its lipophilic character. It is really prone to protein 
binding assays matrix effects (something in the sample tubes, which is not in the 
standard tubes causes matrix effects, which alter the ability of binding agent, antibody, 
or binding protein to associate with 25(OH)D from the way of which they associate with 
the standard) (see Hollis, 2008). 
The two approaches to measure 25(OH)D are competitive immunoassays and 
methods based on chromatographic separation followed by direct detection (see Wallace 
et al., 2010). The first method to measure 25(OH)D was a competitive protein binding 
assay (CPBA) by Haddad in 1971. The assay measures circulating 25(OH)D by using 
DBP as a primary binding agent and Human-25(OH)D? as a reporter. The method is 
challenging because, the sample has to be extracted with organic solvent, dried with 
nitrogen and purified using column chromatography. The procedure requires also 
sample 25(OH)D concentration estimation, because of endogenous loss during the 
method.  The  CPBA  of  Haddad  has  been  tried  to  modify  towards  an  easier  procedure  
involving no chromatographic purification, but those attempts had other problems like 
matrix problems due to ethanolic sample extraction (see Hollis, 2008). Today CPBA is 
a rarely used method because of its cumbersome character. In the early 1980s the group 
of  Hollis  came  up  with  a  radioimmunoassay  (RIA)  where  an  antigen  is  used  that  
generates an antibody specific for 25(OH)D? and 25(OH)D?. It is a simple non-
chromatographic quantification. In 1992 125-I-labeled reporter and calibrators as well 
as standards for mass assessment were introduced. The method is good because of its 
accuracy in detecting the whole circulating 25(OH)D content of the sample. A few 
manufacturers are on the market with RIAs. Some of them detect both 25(OH)D? and 
25(OH)D? (see Hollis,  2008).  The unfavourable aspect of the RIA is the nature of the 
radioactivity where special trained personal has to be performing the method. The 
strengths of RIAs are the relative inexpensiveness, the minimization of matrix effects 
after solvent extraction and the ease of handling. The drawbacks are the solvent 
extraction, creation of radioactive waste and possible lot variation (see Wallace et al., 
2010). 
 High performance liquid chromatography (HPLC) is considered to be the 
standard method to measure 25(OH)D status at the moment. The method separates and 
quantificates 25(OH)D? and  D? individually. The method is good because it is highly 
repeatable. The down side of the HPLC is that it is cumbersome. It requires large 
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sample size and a radioactive internal standard. The sample throughput is slow and a 
technician has to be highly trained and dedicated to complete the task (see Hollis, 2008). 
Liquid chromatography-mass spectrometry (LC-MS) quantificates D? and  D? 
metabolites separately. It is a good method because it is really accurate and sample 
throughput is larger than in HPLC. Its down sides are that it is really expensive and it 
needs an internal standard for each component. Also LC-MS needs highly trained 
personal to perform the analysis. It also has a special problem: it does not distinguish 
between 25(OH)D? and its inactive form 3-epi-25(OH)D? (see Hollis, 2008). Still it is 
thought to become the new gold standard method for 25(OH)D measurement because of 
its accuracy. Enzyme immunoassays (EIA) are also used to determine 25(OH)D status 
from serum or plasma. The advantages of the EIA are the ease of handling, the relative 
inexpensiveness and the safety due to no radioactivity. Most EIAs also measure both 
25(OH)D? and 25(OH)D?. The drawbacks however are the susceptibility to matrix 
effects, the possible variation between lots and the possible underestimation of 
25(OH)D? (see Wallace et al., 2010). 
1.4.2 The International Quality Assessment Scheme for Vitamin D metabolites 
(DEQAS) 
The International Quality Assessment Scheme for Vitamin D metabolites (DEQAS) was 
founded in 1989. It was established to control the reliability of 25(OH)D measurement 
assays (see Kimball and Vieth, 2007). In 1997 it expanded to control also the quality of 
1,25(OH)?D measurement methods. The number of participating laboratories has grown 
from 25 in 1989 to over 100 in 18 countries in 2004 (see Hollis, 2004). The number of 
participants has in 2010 reached almost 700 laboratories (Figure 5). 
 The participating laboratories receive five normal human serum samples for 
total 25(OH)D measurement every three months and have about five weeks to report 
their results for the statistical analysis (Carter et al., 2004, www.deqas.org). Samples 
usually contain only 25(OH)D? but occasionally also 25(OH)D?.  The  serum  samples  
are posted in January, April, July and October. Before distributing them to participants 
the samples are screened for Human Immunodeficiency Virus (HIV), Hepatitis B and C. 
The “true” target value is created using gas chromatography-mass spectrometry 
(see Zerwekh, 2008). When the statistical analysis has been made all participants 
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receive  a  report  via  e-mail  or  post  with  the  All-Laboratory  Trimmed  Mean  (ALTM),  
Standard  Deviation  (SD)  and  Coefficient  of  Variance  (CV)  for  every  sample.  The  
accuracy of each result is measured by the percentage amount it differs from the ALTM. 
All results are also grouped by their method and therefore create a method mean (MM). 
The overall method accuracy is counted by this formula:  
 
{[(MM – ALTM)/ALTM] x 100} (Carter et al., 2004). 
 
All results can be found on the Internet (since 2004) if the laboratory is participating in 
the survey. Results are not available for third part individuals. The report also includes 
the ALTM, SD and CV by major method groups and individual histograms. When 
participants return their results via Internet, the updated statistics and histograms are 
immediately available to the participant (www.deqas.org). 
The methods which correlated best with the ALTM in the four-year comparison 
from 2000 to 2004 were the RIA from Diasorin and the competitive protein binding 
assay. The method which varied the most from the mean ALTM was the Nichols 
automated chemiluminescence method (Carter et al., 2004). The Figure 10 shows the 
number of participated laboratories illustrated together with the number of each method 
used in January 2010. The number of participating laboratories has grown from 609 in 
October 2009 to 689 in January 2010. More and more laboratories seem to recognise the 
importance of adequate quality control monitoring in 25(OH)D measurement methods.   
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Figure 10. Number of laboratories participating in the survey in January 2010 dealt to different 
blocks depending on method. 
 
The popularity of immunoassays is clearly seen in the reports of the DEQAS assessment 
group. The number of different methods in January 2010 is clearly dominated by 
immunoassays (automated IDS EIA, Diasorin RIA, IDS EIA, IDS RIA, IDS-ISYS, 
Roche 25OHD3 and Diasorin Liason) (Figure 10). The most popular method was the 
Diasorin Liason method and the second most used was the manual EIA from IDS. 
If one wishes to check the accuracy of ones method but can not take part in the 
DEQAS survey, one can purchase samples when needed. For 25(OH)D the amount for 
ordering is GBP150 per year. After reporting results a full statistical analysis is made by 
the DEQAS. 
 The DEQAS advisory panel consists of scientists with expertise in vitamin D 
methodology and/or quality assessment schemes. If a scientist has problems regarding 
sample preparation and distribution, vitamin D methodology, statistical analysis and 
data presentation or setting of performance targets the panel is happy to help with these 
questions. When a laboratory has met the performance target set by the DEQAS 
Advisory panel it will receive annually a proficiency certificate from the panel 
(www.deqas.org). Another quality control assessment scheme is the EQAS for vitamin 
D measurement assays. As the DEQAS is located in the United Kingdom this one is 
located in Finland (www.labquality.fi). Twice a year they send two serum samples for 
participants and provide a statistical analysis of the results. The true value here is 
generated using HPLC atmospheric pressure ionization electro spray (API-ES) MS 
(www.labquality.fi). 
2 Objectives 
Hypothesis 
Low serum vitamin D status during first trimester of pregnancy increases the risk of 
T1D development in the offspring.  
2.1 Aim of this study  
The aim of this study was to solve if vitamin D is one environmental factor associated to 
T1D development, especially if vitamin D status of the mother during the first trimester 
of pregnancy has any effect on T1D prevalence in the offspring. Serum 25(OH)D 
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measurements were done to compare the status of mothers with T1D offspring and 
mothers with healthy offspring. This study is part of a more comprehensive study. 
3 Materials and methods  
3.1 Finnish Maternity Cohort 
The Finnish Maternity Cohort is a serum bank, which in the end of 2006, hold up over 
1.3 million samples collected from 720 000 female donators (Toriola et al., 2009). It is 
therefore the world`s largest serum bank for female donors. It was established in 1983 
by the National Institute for Health and Welfare. Over 98% of pregnant women in 
Finland  have  given  a  sample  to  the  serum  bank.  If  withdrawal  has  occurred  after  
1.5.2001 informed consent is needed (www.thl.fi). Samples withdrawn before that are 
stored and used for research aiming for population based health promotion, due to the 
law considering this, which came into force 1.5.2001. The samples are withdrawn at a 
municipal maternity clinic during the first trimester of pregnancy. The reason for taking 
these serum samples is to screen for infections. When the screening is done, the 
remaining sample (1-3 ml) is stored at the laboratory of maternity serology at the 
National  Institute  for  Health  and  Welfare  in  Oulu,  Finland  (www.thl.fi).  The  samples  
are stored at -25 ºC in polypropylene cryo vials. The samples are used for assessing the 
association of various biomarkers to diverse diseases of either the mother or the child 
(www.thl.fi, Toriola et al., 2009). 
3.2 Samples 
The study was designed as a case-control study where cases were matched with controls 
for serum sample withdrawal date. The cases were identified from the National Institute 
for Health and Welfare T1D database by identifying all in or after 1994 born T1D 
offspring and therefore the whole family and especially the mother. Samples from 310 
women with T1D offspring and 310 women with healthy offspring were analysed for S-
25(OH)D. The samples were all-year-round samples, where the control was always 
matched with the case for sample withdrawal date. The contact information was 
provided by the Population Register Centre of Finland. Written consent was collected 
from all participants. Serum samples were stored at -20 ºC until analysed. 
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3.3 25-hydroxyvitamin D measurement 
The method, to measure the serum 25(OH)D concentration, used was the IDS OCTEIA 
enzyme immunoassay (EIA) (Immunodiagnostic Systems Ltd.). This method is done on 
a 96-well microtiter plate, which has a specific 25(OH)D-antibody attached to the wells. 
It is an indirect detection method, meaning that the 25(OH)D content of the samples is 
not measured directly but through a competing labelled 25(OH)D. The sensitivity, 
meaning the concentration corresponding to the mean minus two standard deviations of 
ten replicates of the zero calibrator, of the kit is <6 nmol/l (IDS Ltd.). The specificity of 
the kit regarding vitamin D metabolites is shown in Table 7. Nevertheless the overall 
amount of further hydroxylated metabolites in the circulation is quite small (? 6%) and 
can be seen as insignificant (see Zerwekh, 2008). The CVs that should be reached for 
intra-assay and interassey recommended by the manufacturer are <8% and <10% 
respectively. The assay detects a S-25(OH)D concentration range between 6 and 360 
nmol/l. The samples that can be analysed by this method are serum or plasma samples 
and the amount needed for single determinations is 12.5 µl. When samples are analysed 
by single determination 76 samples can be analysed on one plate.  
 
Table 7. Cross-reactivity to vitamin D metabolites  
Metabolite Cross-Reactivity 
25(OH)D? 100 % 
25(OH)D? 75 % 
24,25(OH)?D? ?100% 
D? <0.01% 
D? <0.30% 
 
Controls and calibrators provided by the manufacturer are lyophilised, buffered human 
serum samples containing 25(OH)D and <1% sodium azide. Samples, kit controls and 
calibrators are first diluted with biotin labelled 25(OH)D (lyophilised buffer containing 
25(OH)D labelled with biotin and stabilizers). To 12.5 µl of sample 500 µl of 25(OH)D-
biotin solution is added. When diluting controls and calibrators, 25 µl of 
calibrator/control is added to 1 ml of 25(OH)D-biotin solution. The solution is added to 
all to ensure the dissociation of vitamin D from its binding proteins. The mixture is 
vortexed thoroughly and 200 µl of each is added to the anti-25(OH)D coated (25(OH)D 
sheep polyclonal antibody) plate where the biotin labelled 25(OH)D and the samples 
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25(OH)D compete to bind the antibody. The plate is then incubated at room temperature 
for two hours. After incubation the plate is washed trice with the plate washer (300 µl of 
phosphate buffered saline containing Tween per well per cycle) to remove any unbound 
and excess biotin labelled 25(OH)D. To detect bound 25(OH)D-biotin conjugate, 200 µl 
of avidin horseradish peroxidase (HRP) is added to each well and incubated for 30 min 
at room temperature. After incubating the washing step is repeated. The chromogenic 
substrate used here for avidin-HRP is tetramethylbenzidine (TMB and hydrogen 
peroxide as an oxidizing agent) which forms a blue product when reacting with 
peroxidase enzymes. The reaction mixture is again incubated for 30 min and then 
stopped by adding 100 µl of 0.5 M Hydrochlorid acid (HCl). This turns the product 
yellow and the intensity can be read at 450 nm (650 nm). The absorbance is inversely 
proportional to the concentration of 25(OH)D in the samples. The more intense the 
colour formation the more biotin labelled 25(OH)D and the less 25(OH)D originating 
from the samples is present. The method is illustrated in Figure 11. The results are 
calculated by the standard curve composed of the calibrators 0-6 which have 25(OH)D 
concentrations of 0 nmol/l, 6.8 nmol/l, 14.0 nmol/l, 27.0 nmol/l, 67.0 nmol/l, 179.0 
nmol/l  and  380  nmol/l.  The  results  were  processed  computationally,  to  create  a  B/Bo  
standard curve and therefore calculate the S-25(OH)D concentrations of the samples.  
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Add 12,5 µl sample Add 500 µl/1 ml 25(OH)D-Biotin Add 200 µl of 
Solution mixture to plate
Add 200 µl Avidin HRP                            Wash 3x                            Incubate 2 
hours RT
Incubate 30 min RT Wash 3x
Incubate 30 min Add 200 µl 
TMB substrate 
to plate
Add 100 µl stop reagent
to plate
read absorbance at 450 nm
 
Figure 11. Serum-25(OH)D measurement method with EIA. 
 
To improve repeatability and reliability all samples were analysed using a single batch 
of assay kits and analysed in the same laboratory (University of Helsinki, Department of 
Food and Environmental Sciences, Finland). Cases and matched controls were always 
analyzed in the same intra-assay. The repeatability and reliability was inwardly assessed 
with controls provided for each kit by the manufacturer and one own (Pool) sample of 
the laboratory. The CVs for intra- and interassay were 3.57% and 3.68% and therefore 
remained in the recommended values. The quality control was further strengthened by 
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participating in the DEQAS during this work (processing of DEQAS samples in 
October  2009).  The  own results  seemed to  be  slightly  higher  than  the  ALTM and the  
MM (Figure 12). The CV for the IDS EIA was 12.9 %. The bias from the ALTM and 
MM are shown in Table 8. This method gives higher values than both the ALTM and 
the MM. The method usually gives lower concentrations than the ALTM (Method 
accuracy [(MM – ALTM)/ALTM] x 100 = -2,67). 
 
Table 8. Bias from ALTM and MM in October 2009. 
Sample Bias from ALTM (nmol/l) Bias from MM (nmol/l) 
361 20.9  25.1  
362 2.8  10.2  
363 4.2  8.5  
364 13.2  14.2  
365 24.6  22.7  
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Figure 12.  Comparison of own results to ALTM and MM in October 2009. 
 
S-25(OH)D concentration below 25 nmol/l was considered to indicate vitamin D 
deficiency, concentrations between 25 and 50 nmol/l to indicate insufficiency and 
concentrations between 50 and 80 nmol/l to indicate sufficiency. Concentrations over 80 
nmol/l were considered to indicate optimal level of S-25(OH)D.  
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3.4 Laboratory equipment 
The samples were diluted for analyses in polypropylene tubes to prevent the 25(OH)D 
in sticking to the tubes. Precision pipetting device to deliver 12.5 µl, 25 µl, 200 µl and 1 
ml were used. Repeating pipetting devices to deliver 500 µl and 1 ml were used. To add 
samples and reagents to microwells, precision pipetting device to deliver 200 µl and 
multichannel pipette to deliver 200 µl and 100 µl were used. Highly purified water was 
used for solubilisation of controls and calibrators. Plates were washed with an automatic 
plate washer dispensing 300 µl per well and aspirating during three cycles per washing 
step. The absorbance was measured by a photometric plate reader at 450 nm and 650 
nm. The results were calculated with a curve-fit software.  
3.5 Statistical analysis 
Statistical analysis was carried out using SPSS 15.0 for Windows (SPSS Inc., Chicago, 
USA).  The  variables  were  tested  for  normality  and  a  paired  t-test  was  performed.  A  
two-sided p < 0.05 was considered statistically significant. Normally distributed data 
was presented as means and standard deviation. 
4 Results 
4.1 Vitamin D deficiency in the whole study population 
When considering the whole study population 72% (N=445) had insufficient or 
deficient S-25(OH)D status (<50 nmol/l) during the first trimester of pregnancy. Only 
26% (N=162) had sufficient (50-80 nmol/l) status and 2% (N=13) optimal (>80 nmol/l) 
status (Figure 13).  
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Figure 13. Vitamin D status in Finnish pregnant women. The situation of the whole study 
population. 
 
4.2 Vitamin D status comparison between mothers with healthy offspring and 
mothers with T1D offspring 
The S-25(OH)D concentrations did not differ between cases and controls (p=0.748) 
(Figure 14, Table 9). The percentage of women having a S-25(OH)D below 25 nmol/l, 
meaning deficient status was 9.7% in the case group and 8.7% in the control group (Fig. 
9). The biggest group in both study groups was the one with S-25(OH)D concentrations 
between 25 nmol/l and 50 nmol/l which is characterized as insufficient status. There the 
percentage of women from the case group was 61.0% and from the control group 64.1% 
(Figure 14). Sufficient S-25(OH)D status (50-80 nmol/l) was reached by 27.4% and 
28.7% of cases and controls respectively (Figure 14). Optimal status of S-25(OH)D 
(>80 nmol/l) was measured in 1.9% of cases and 2.3% of controls (Figure 14). Mean S-
25(OH)D concentration in cases was 43.3 ± 15.9 nmol/l (Mean ± SD) and 43.0 ± 15.5 
nmol/l in controls. 
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Figure 14. Serum-25(OH)D concentration between control and case groups measured from samples 
during first trimester of pregnancy. 
 
Table 9. Statistical variables for different S-25(OH)D concentration groups. 
 Cases     Controls     
S-25(OH)D N Range Mean Median SD N Range Mean Median SD 
0-25 nmol/l 30 15.7-25.0 21.99 22.69 2.81 27 14.3-25.0 22.20 23.48 2.82 
25-50 nmol/l 189 25.5-49.7 37.04 36.59 7.02 199 25.5-49.9 37.20 36.79 6.96 
50-80 nmol/l 85 50.7-77.7 61.31 58.87 8.33 77 50.1-77.6 60.74 58.91 7.49 
>80 nmol/l 6 82.7-100.5 92.09 92.46 6.53 7 81.5-114.9 92.00 89.50 11.47 
Total 310 15.7-100.5 43.30 39.88 15.93 310 14.3-25.0 42.98 40.85 15.50 
 
5 Discussion 
The presented results show a high incident of vitamin D deficiency in pregnant women 
in Finland. This is the first study to assess this during first trimester of pregnancy in 
Finland. The mean concentrations in both control and case groups were barely half of 
the concentration considered as a lowest value for optimal status. This is a result 
presented by numerous studies (Holmes et al., 2009, Toriola et al., 2009). Low statuses 
of S-25(OH)D may be due to the reason that recommended doses for pregnant women 
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for vitamin D are quite low (10µg per day) and they are not followed. The results are an 
overall mean for the whole year. Holmes et al. (2009) showed in their study that vitamin 
D supplementation of pregnant women did neither prevent vitamin D deficiency (<25 
nmol/l) during winter and spring time nor prevent insufficiency (<50 nmol/l) during the 
whole year. 
No significant relationship between low S-25(OH)D during pregnancy and risk 
of T1D development in the offspring was observed. The study Fronczak et al. (2003) 
and the study of Stene et al. (2000) both showed that association between risk of T1D in 
the offspring was associated to vitamin D intake via natural sources but not 
supplements. This could indicate that the beneficial effect of vitamin D on T1D 
prevention in the offspring is only achieved with the help of some other metabolites 
(vitamin A, fatty acids) together with vitamin D. Also in the study of Hyppönen et  al.  
(2001)  it  is  difficult  to  say  if  the  positive  effect  was  due  to  vitamin  D,  the  combined  
effect of vitamin A and D or just vitamin A supplementation, due to the fact that 
vitamin D and A supplementation was combined in one supplement at the time of the 
study (Ala-Houhala et al., 1995). Another possible reason for the natural vitamin D to 
be more efficient in T1D prevention is the fact that it is metabolized differently in the 
body than synthetic forms found in supplements. Former studies where the association 
between vitamin D status and T1D development in the offspring has been show might 
also be due to false positive results. In this study no association was observed and also 
impossible to detect for the reason that all concentrations were low.  It might be possible 
that some Finnish mothers still avoid fish and mushrooms in their diet, due to the 
warnings that fish might contain to much mercury and mushrooms might contain 
radioactive compounds resulting from the Chernobyl disaster in 1989. The mothers 
hence consume vitamin D not from natural sources but from supplements if they follow 
the recommendations. Lamberg-Allardt et al. (1984) investigated the S-25(OH)D 
concentrations at time of delivery from maternal and cord blood and also the vitamin D 
intake of mothers in Finland. They showed that the intake (5.5 µg/d) did not meet the 
recommendations of the Food and Nutrition board at that time (10 µg). They also 
showed that mothers who consumed vitamin D supplements had higher S-25(OH)D 
concentrations than mothers who did not consume supplements (87 nmol/l vs. 59 
nmol/l). Studies where there has been a beneficial effect of mothers S-25(OH)D during 
pregnancy and lower risk of T1D in the offspring have not been reported. It might be 
that low vitamin D status is associated to T1D development in the offspring only when 
genetic factors are prevalent also. These genetic factors can be readily investigated in 
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this study population due to the fact that the S-25(OH)D concentrations are so similar in 
cases and controls. 
Narchi et al. (2010) showed in their study that S-25(OH)D concentrations of 
pregnant women lowered during pregnancy. They measured the concentrations once at 
antenatal  visit,  once  after  birth  and  once  6  months  after  birth.  The  amount  of  women 
having adequate status fell from 31% to 23% and finally 17% respectively.  This could 
suggest that if possible serum samples from later stages of pregnancy and possibly close 
to child birth should be analysed for S-25(OH)D to see if this decrease in S-25(OH)D 
concentration is also obtained in the present study. Unfortunately samples from later 
stages of pregnancy are not available. Holmes et al. (2009) indicated that the increased 
maternal calcium absorption together with increased renal calcium loss during 
pregnancy leads to significant changes in vitamin D metabolism. They measured the S-
25(OH)D statuses during pregnancy at 12 weeks (1st trimester), 20 weeks and 35 weeks 
gestation. Vitamin D deficient (<25 nmol/l) were 35%, 44% and 16% and insufficient 
(<80 nmol/l) were 96% (12 and 20 weeks) and 75% at these measurement points. This 
indicates that the S-25(OH)D status was lowest at 20 weeks of gestation. It could be 
possible that the foetal demands for calcium and vitamin D are highest at this stage of 
pregnancy and hence this could be a critical point for maternal vitamin D status during 
pregnancy.  
Strengths of this study include the population-based nature and the prospective 
nature. The FMC contains samples of 98% of Finnish women and the samples were 
collected before offspring T1D diagnosis and invitation to this study. Study subjects 
have not been possible to change their eating habits or intake of vitamin D supplements 
for this study. A limitation is the absence of samples during later pregnancy and time of 
child birth which could give further information about the possible effects of vitamin D 
on T1D development. But these samples are not available. 
6 Conclusions 
In conclusion S-25(OH)D status during pregnancy 1st trimester is not associated to T1D 
development in the offspring. Other samples from during pregnancy and close to birth 
should be analysed to assess if the S-25(OH)D concentration during whole pregnancy is 
associated to T1D development in the offspring. This unfortunately is impossible due to 
the fact that samples from later stages of pregnancy are not available. This study 
showed for the first time in Finland that the prevalence of vitamin D deficiency and 
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insufficiency  is  high  in  pregnant  women  also  at  the  first  trimester  of  pregnancy.  The  
vitamin D recommendations should be raised in order to provide adequate statuses for 
the whole population. The following of the recommendations should be monitored 
somehow and vitamin D supplements could be given for free to pregnant women during 
their first visits at maternity clinics. 
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